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Nowadays, around 100 different diseases sort under the umbrella of rheumatic diseases(1). 
They involve different mechanisms and symptoms engaging joints, tendons, ligaments, 
bones, muscles but also vital organs like the kidneys nervous system and circulation. The 
diagnoses is dependent on a combination of common clinical manifestations and laboratory 
findings such as the presence of specific antibodies that target self-antigen (2–4). Rheumatic 
disease evolves from a complex interplay between genetic, stochastic and environmental 
factors resulting in a loss of immune tolerance. B-cell targeting agents have proven useful in 
the treatment of several rheumatic diseases. Rituximab, a chimeric monoclonal antibody 
targeting CD20, is e.g. used in rheumatoid arthritis (RA) patients who do not respond to 
tumor necrosis factor (TNF) inhibitors and as off label-rescue treatment in systemic lupus 
erythematosus (SLE). Additionally, belimumab, a B cell activating factor (BAFF) inhibitor, 
is the first approved biological drug for SLE. Even though B-cell targeting therapies are 
commonly used, little is known about the effect of these therapies on disease associated B 
and T cell subsets, such as age/autoimmune-associated B cells (ABCs) and T follicular helper 
(Tfh) cells.  
In paper I, we therefore studied the effect of these two subsets in response to rituximab 
treatment in SLE patients and found that ABCs are indeed influenced by the treatment while 
Tfh frequencies stayed similar to baseline. Additionally, we observed a decrease frequency 
of programmed cell death protein 1 (PD-1) high CD4+ T cells.  
In paper II, we investigated the effect of belimumab on circulating B and T cell phenotypes 
in SLE patients using mass cytometry and correlated them with clinical response. Belimumab 
had rapid effects on B cell subsets of earlier developmental stages such as naïve B cells while 
late B cell stages, such as memory or plasma cells, decreased later in a gradual manner or did 
not change upon treatment. Only early immunological changes correlated with disease 
improvement. High B cell counts at baseline were associated with late or non-responders.  
Not all patients respond to B-cell targeting therapy, highlighting the heterogenicity of SLE. 
To develop novel therapies, a better understanding of the underlying mechanisms related to 
clinical phenotypes is needed.  
Thus, in paper III, we explored the cytokine profile and the cellular composition in the 
synovial fluid of lupus arthritis patients, and we found elevated levels of IL-6 and IL-17A in 
the joint. Furthermore, we found an enrichment of Th17, peripheral helper T cells and 
EOMES/Granzyme A-expressing T cells in synovial fluid of SLE patients. All in all, 
indicating a potential role of Th17 cells in the pathogenesis of lupus. In contrast to lupus 
 
 
arthritis, RA patients exhibit a more aggressive form of arthritis, especially in conjunction 
with anti-citrullinated protein autoantibodies (ACPA).  
Therefore, in paper IV, we investigated the citrulline-specific B cell population in RA 
patients using an antigen-tetramer enrichment technology followed by single cell sequencing 
of the immunoglobulin genes. We discovered that the broad ACPA specificity in RA patients 
might develop from clonal expansion of a few B cell clones. Furthermore, monoclonal 
antibodies which originated from citrulline reactive B cells were multi-reactive and able to 
promote pain-like behavior and joint inflammation in mice.  
 
Overall, this thesis explored immunological changes upon B-cell-targeting therapy and 
pathogenicity in joint inflammation in SLE and seropositive RA patients. We provided new 
understanding of B-cell targeting therapies on B and T cell subsets in SLE patients as well as 
the pathogenic mechanism which might be involved in lupus arthritis. Additionally, we 
examined the citrulline reactive B cell repertoire in RA patients and our data reveal their 
potential origin.  
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LIST OF ABBREVIATIONS 
 
ABCs Age-associated B cells / autoimmune-associated B cells 
ACPA Anti-citrullinated protein autoantibodies 
APRIL A proliferation-inducing ligand  
BAFF B-cell activation factor 
BAFFR/BR3 B-cell-activating factor Receptor 
BCMA B cell maturation antigen 
BCR B cell receptor  
BM Bone marrow  
C1q Complement component 1q 
cAMP  Cyclic adenosine monophosphate 
CBA Cytokine bead array 
CCP Cyclic citrullinated peptides 
CCR CC Chemokine receptors 
CD Cluster of differentiation 
CDR  Complementarity-determining regions 
cDC Classical dendritic cells  
CEP1 Cyclic enolase peptide 1 
Cfc Circular citrullinated peptides from filaggrin  
CRP  C reactive protein  
CSF Cerebrospinal fluid  
CVID Common variable immunodeficiencies  
CXCL Chemokine (C-X-C motif) ligand  
CXCR Chemokine (C-X-C motif) receptor  
DHEA Dehydroepiandrosterone 
DNA Deoxyribonucleic acid 
ELISA Enzyme-linked Immunosorbent Assay  
EOMES  Eomesodermin 
EXPLORER The Exploratory Phase II/III SLE Evaluation of Rituximab 
Fab Fragment antigen-binding 
Fc Fragment crystallizable region 
FcRL5 Fc Receptor Like 5 
FO Follicular   
GC Germinal center  
GZMA  Granzyme A  
 
 
HLA Human leukocyte antigen  
IFN Interferon  
Ig Immunoglobulin 
IL Interleukin  
IQR Interquartile range  
IRF Interferon regulatory factors 
LLDAS Lupus low disease activity score  
LN Lupus nephritis 
LN Lymph node 
LUNAR Lupus Nephritis Assessment with Rituximab study 
mAb Monoclonal antibody  
MHC Major histocompatibility complex ( 
MS Multiple sclerosis 
MZ Marginal Zone 
NET Neutrophil extracellular traps  
NF-kappa B  Nuclear factor kappa B  
NK Natural killer  
P.gingivalis Porphyromonas (P.) gingivalis 
PAD Peptidylarginine deiminase 
PBMC Peripheral blood mononuclear cells 
PC Plasma cell 
PC Principal component analysis  
PD Programmed cell death protein 1   
pDC Plasmacytoid dendritic cell 
PE  Phycoerythrin 
PTPN22 protein tyrosine phosphatase non receptor type 22 gene 
RA Rheumatoid Arthritis 
RA33 Ribonucleoprotein A2/B1 
RF Rheumatoid Factor 
RNP Ribonucleoprotein particle 
ROCK2 Rho-associated protein kinase  
RORγt Related-orphan nuclear receptor γt  
SA streptavidin  
SE Shared epitope 
SF Synovial Fluid 
SS Sjögren's syndrome 
SLE Systemic Lupus erythematosus 
SLEDAI SLE Disease Activity Index  
SNP Single nucleotide polymorphism 
SRI  SLE responder index  
SSA/Ro Anti–Sjögren's-syndrome-related antigen A autoantibodies 
SSB/La Anti–Sjögren's-syndrome-related antigen B autoantibodies 
ST Synovial tissue  
T-bet  T-box transcription factor TBX21 
TACI T cell activator and calcium modulating ligand interactor 
TCR T cell receptor  
TEMRA   Effector memory T cells re-expresses CD45RA 
Tfh  T follicular helper  
Th T helper cells  
TLR Toll-like receptor  
TNF Tumor necrosis factor  
TPH T peripheral helper  
Treg T regulatory cells  
tSNE  t-Distributed Stochastic Neighbour Embedding  
VH Variable heavy gene  






Rheumatic diseases are initiated through a complex interplay between genetic and 
environmental risk factors and stochastic changes, resulting in a break of tolerance, 
autoantibody production and subsequently clinical symptoms (5). The disease diagnosis and 
therapy are linked to clinical manifestations and laboratory measures, such as the presence 
of specific autoantibodies. B cells have gained attention in the pathogenic role of rheumatic 
and other autoimmune diseases due to the success of B-cell targeting therapy. This thesis 
focuses on the two rheumatic diseases: systemic lupus erythematosus (SLE) and rheumatoid 
arthritis (RA). Here, we explored the effect of two B-cell targeting therapeutic agents 
belimumab and rituximab on T and B cell phenotypes in SLE patients, as well as the 
underlying mechanisms of synovitis in SLE. Furthermore, we investigated the citrulline-
specific B cells repertoire and origin in RA patients along with their contribution in the 
pathogenesis of RA. 
1.1 RHEUMATOID ARTHRITIS (RA)  
Rheumatoid arthritis (RA) affects around 0.5-1% of the world population of all ethnicities 
with an onset of age between 40 and 70 and is more prevalent in women compared to men 
(6,7). RA is characterized by chronic inflammation of the synovial joints in which 
predominantly small joints in the digits and extremities are affected in a symmetrical pattern. 
However, larger joints, such as the knee, hip and shoulder, can also be involved (6) .The 
inflammation in the joint induces pain, tenderness and if not treated, can lead to disabilities 
and premature mortality (6). RA is classified by the presence of synovitis in at least one joint 
in the absence of other diagnostic alternatives, duration, location of the joint as well as 
laboratory findings, such as acute-phase reactants and RA-related autoantibodies (serology) 
(2). Two types of autoantibodies have been assoicated with RA and are nowadays used as 
diagnostic tools: rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) (2). 
The characterization and association of these autoantibodies with the disease are discussed 








Figure 1: Joint inflammation in RA is characterized by immune cell infiltration, high levels 
of proinflammatory cytokines (IL-6, TNF), activation of osteoclasts and the presence of 
autoantibodies and immune completes.  
1.1.1 Rheumatic Factor (RF)  
Rheumatoid Factor (RF) was discovered in 1940s and named after the association with RA 
(8). RF targets the fragment crystallizable region (Fc) region of the immunoglobulin (Ig) G 
and can be found in around 70% of RA patients (9). Although, RF is commonly used as 
diagnostic marker, it is rather unspecific, since it can also be detected in other autoimmune 
diseases, such as Sjögren syndrome (SS) and systemic lupus erythematosus (SLE), as well 
as in some healthy subjects and it increases with age (10). RF enhances immune complex 
clearance, by increasing B cell uptake of immune complexes and antigen presentation as well 
as complement fixation on immune complexes (11). Under normal conditions, RF is 
suggested to be produced by secondary immune responses. 
 
In RA, increased titers, high affinity RF and the isotype IgA have been linked with bone 
erosion, severity and persistent disease (11–13). It has been proposed that RF is introduced 
from autoantibody formed immune complexes and contributes to the disease by forming 
immune complex and fixating complement which leads to tissue damage (11). Interestingly, 
RF derived from healthy individuals and RA patients exhibits similar characteristics. RF is 
of low affinity with moderate somatic maturation (14).  
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These results were replicated by Lu et al. together with the finding that RF positive B cells 
exhibit a specific transcriptional program which was associated with a rapid memory 
reactivation driven by multiple innate immune pathways such has Toll-like receptor (TLR) 
stimulation (15).  
1.1.2 Anti-citrullinated protein antibodies (ACPA)  
Antibodies directed towards citrullinated proteins are detected in 70% of RA patients and 
ACPA+RA patients have been shown to suffer from a more severe disease progression 
including aggressive bone erosion and enhanced radiological progression (16–18). In 2010, 
ACPAs were incorporated in the RA classification (2). For diagnostic purposes, ACPAs are 
primarily measured using cyclic citrullinated peptide (CCP) IgG ELISAs (19).  
1.1.2.1 Citrullination a post-translational modification  
Citrullination is a post-translational modification of proteins in which the positive charged 
amino acid arginine is converted into a neutral citrulline (20). Citrullination is irreversible 
and alters the conformation, function and half-life of a protein (21,22).  
The modification occurs ubiquitously during cell differentiation, apoptosis and inflammation 
(21). Elevated levels of citrullinated proteins are present in several diseases such as multiple 
sclerosis, Alzheimer, inflammatory bowel disease and cancer, without the presence of 
ACPAs (23,24). This reaction is catalyzed by the enzyme peptidylarginine deiminase (PAD), 
which requires high levels of calcium.  There are five different isotypes of the PAD enzyme 
in the human body, PAD1, PAD2, PAD3, PAD4 and PAD6 and they are distributed in a wide 
range of cell types and tissues (25). 
1.1.2.2 Prevalence of ACPAs 
ACPAs are only rarely found in other autoimmune diseases and in less than 2% of healthy 
individuals (26–28). Retrospective studies revealed that ACPAs can be present many years 
before onset of the disease (29). However, shortly before clinical onset of RA, ACPA titers 
increase and the ACPA profile broadens (30,31). Studies have shown that in 90% of patients 
with undifferentiated arthritis, such as joint pain or musculoskeletal symptoms, and ACPA 
positivity confers a risk of RA development suggesting the potential pathogenic role of 






1.1.2.3 Genetic and environmental Risk factors  
Several genetic and environmental factors have been associated with ACPAs. The most 
prominent genetic predisposition is the so-called shared epitope (SE) in the human leukocyte 
antigen – certain DR isotype 1 (HLA-DRB1) variants e.g. HLA-DRB1*0401, *0404, *0101 
and *1001.  
 
The second strongest genetic predisposition is located in the protein tyrosine phosphatase 
non receptor type 22 gene (PTPN22). PTPN22 encodes the protein lymphoid tyrosine 
phosphatase which negatively regulates T and B cell activation (34,35). An increase in a 
cytotoxic phenotype of T cells, Eomesodermin (EOMES+) CD4+ T cells with a more 
pronounced production of Perforin-1 has recently been described in PTPN22 risk allele 
carriers (36). 
1.1.2.4 Environmental risk factors for ACPA+RA 
Environmental risk factors include air pollution such as smoking and inhalation of silica dust 
but also infectious agents (37,38). A strong interaction between the genetic risk factor HLA-
SE alleles, smoking and ACPA positivity has been demonstrated, pointing towards a possible 
model for the aetiology of seropositive RA (38–40).  
Recently, a connection between periodontitis and RA has been reported. Interestingly, the 
bacterium porphyromonas (P.) gingivalis, which is implicated in periodontitis, a chronic 
inflammatory oral disease, expresses a PAD enzyme and is therefore able to citrullinate 
proteins, which could suggest a model of molecular mimicry (41). This theory is further 
supported by the finding, that ACPAs are able to bind with citrullinated peptides from the 
bacterium P.gingivalis (42). 
1.1.2.5 Characteristics of ACPAs 
Numerous citrullinated proteins have been identified as targets for ACPAs, including 
filaggrin, fibrinogen, collagen type II, histones, alpha-enolase, tenascin-C and vimentin (43–
47). Except for type II collagen, ACPAs most exclusively bind to the citrullinated form of 
these proteins. ACPAs have been identified as multi-reactive towards several citrullinated 
human proteins and peptides which appear to result from the recognition of ACPAs to 
specific motifs rather than specific proteins (48,49). Indeed, a recent study identified ACPAs 
which bound to a spectrum of modified proteins and extended the previously reported set of 




ACPAs exhibit a high level of somatic mutations and distinct glycosylation pattern in the Fc 
and fragment antigen binding (Fab) region (48,51). Fc-glycan profiles in polyclonal ACPA‐
IgG exhibit a more pro-inflammatory profile with decreased terminal galactose and sialic 
acid residues, which is acquired prior to disease onset of RA (52–54). Fab-glycans, which is 
only accounted by 10-25% of IgG antibodies in the periphery and mainly originate from 
somatic mutations (55,56), are enriched in ACPAs and are highly sialylated which changes 
the charge and isoelectric point of the autoantibodies (57,58). Interestingly, antigen binding 
was not altered, which raises the question how and why Fab glycosylation is favored in 
ACPAs (57).  
1.1.2.6 Effector function of ACPAs  
In vitro studies demonstrated the ability of ACPAs to activate complement and interact with 
different cell types. ACPAs can stimulate macrophages through the Fc gamma receptor and 
Toll-like receptor 4 which leads to macrophage tumor necrosis factor (TNF-) production (59–
61). Furthermore, ACPAs are able to induce NETosis of neutrophils, a regulated cell death 
of neutrophils in which neutrophils release a chromatin meshwork with antimicrobial 
peptides called neutrophil extracellular traps (NETs). NETosis is increased in blood and 
synovial fluid (SF) of RA patients and corelates with ACPA concentrations (62). Moreover, 
studies from our rheumatology division have also showed that ACPAs are capable of 
enhancing osteoclast maturation and bone destruction (17,49,63).  
In experimental arthritis models, ACPAs alone are not capable to induce synovitis in mice, 
however, can significantly increase the severity of arthritis if injected with an inducer of 
arthritis (such as collagen II antibodies) (47,64). Even though ACPAs are incapable of 
inducing arthritis alone, intravenous injection of ACPAs reduced trabecular bone mineral 
density in mice. Moreover, injected mice exhibit a long-lasting pain like behavior in absence 
of inflammation. The pain behavior depended on the release of CXCL1/2 by osteoclasts 
which is bound to the receptor CXCR2 on sensory neurons (65). This finding could explain 
the arthralgia that develops before signs of joint inflammation and proceeds in RA patients 

















1.1.2.7 Citrulline reactive B cells in RA  
ACPA positive B cells are enriched in the inflamed joint and circulate in the blood at a 
frequency of ∼1 in 12,500 B cells (61,68,69). Additionally, ectopic germinal centers (GC) 
surrounded by ACPA positive plasma cells have been identified in synovial tissue of RA 
patients (70). ACPA expressing B cells exhibit signs of antigen-experience and are likely to 
be part of the chronic immune responses in RA (71). The majority ACPA positive B cells 
show a class switched memory B cells phenotype and substantial fraction is found in the 
circulating plasmablasts/plasma cells which resembles the dynamics of antigen-specific 
responses(72,73). Moreover, ACPA positive B cells display a high rate of somatic mutation 
and express genes that promote T-dependent B cell differentiation, class switching and 
nuclear-factor kappa B (NF-kappa B) signaling (15). In our unit, Joshua et al. demonstrated 
that ACPA reactive B cells are present in the lungs of seropositive individuals which are at 
risk for or having early untreated RA (74). Besides the lungs, we were also able to 
demonstrate the presence of ACPA positive B cells in inflamed gingival tissue (75).  
These findings suggest that ACPA positive B cells are controlled by RA-specific CD4 T cell 
and repeated GC responses (71) and could originate from extraarticular locations such as the 
respiratory, oral or intestinal mucosa after infections or general immune activation caused by 
smoking or inhaling particles. Increased apoptosis and immune activation might stimulate 
citrullination which, in genetically predisposed individuals, might promote the generation of 
ACPAs. Over the years, ACPAs might undergo epitope spreading. However, it remains still 
unsolved how joint inflammation is initiated and how ACPAs contribute to the pathogenesis 







 ACPAs bind to specific motifs which are found on various proteins/peptides 
 ACPAs are highly somatic hypermutated 
 N-linked-gycosylation motifes are enriched  the Fab region of ACPAs 
 Fc-glycan profile of polyclonal ACPA-IgG changes prior disease onset 




1.2 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 
Systemic lupus erythematosus (SLE) is a heterogenic, systemic autoimmune disease 
involving a spectrum of clinical symptoms ranging from mild to life-threatening disease 
(Figure 2). It is characterized by remission and flares of disease activity and the clinical 
symptoms can differ from acute onset to chronic long-term disease (78,79). 
 
Figure 2: Characteristics of SLE patients. Clinical manifestations of SLE patients according 
to the 2019 classification criteria. Prevalence of SLE is listed below the clinical 
characteristics and immunological features associated with SLE are shown on the right. 
(3,80–82). SLE is associated with the presence of a wide range of autoantibodies, 
proinflammatory cytokines and the consumption of complement. (created by Biorender). 
 
The majority (90%) of SLE patients are females, with  disease onset during the childbearing 
ages, but SLE can manifest at any age (79). The survival rate of SLE patients improved 
dramatically over the last century. However, SLE is still associated with an increased risk for 
mortality compared to the general population (83,84). A recent study discovered that SLE is 
one of the leading causes of death in young women, ranking 10th among 15–24 year old 
females and 20th in females between the ages of 15-64 (85). Nowadays, one of the most 
common causes of death in SLE patients is cardiovascular disease which did not reduce over 
the last decades in comparison to other lupus activity related cause of death, such as renal 
disease (83,86).  
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Clinical manifestations include (87):  
1. Constitutional features include fatigue (53-80%), fever (40-60%), lymphadenopathy 
and weight loss.  
2. Musculoskeletal involvement affects over 80% of SLE patients, especially arthralgia 
(joint pain) which is often present without clinical evidence of inflammation.  
3. Cutaneous skin lesions are common during the disease course, they can give rise to 
many different skin rashes, inclduing the butterfly (malar) rash, but skin manifestaitons 
can also excist as isolated disease (cutaneous lupus erythematosus) which is often 
linked to negative serology and less severe disease (88). 
4. Renal invovlment occurs in 25-55% of SLE patients and is commonly associated with 
a more severe disease and reduced survival  
5. Haematological manifistations consist of anemia (56%), thrombocytopenia, 
leucopenia, lymphopenia (76%) and clotting abnormalitities.  
6. Neuropsychiatric disease include a range of neurological and psychiatric syndrome 
observed in SLE including depression, psychosis (2%), siezures, demyelination (<5%), 
neuropathy and cognitive dysfunction  
7. Cardiorespiratory problems such as pleural disease (45-60%) and  pericarditis (50%)  
Even though women are predominantly affected, men often display a more severe disease 
with regards to both renal and extrarenal manifestations (89).The incidence and prevalence 
of SLE varies between studies, countries and ethnicities. SLE is more common in African 
Americans, Hispanics and Asian Americans who often also show a more severe disease 
course (90). Data from national Swedish registers have shown a prevalence ranging from 46-
85 cases per 100,000 in Sweden. Recent data also demonstrated geographic differences and 
varying female to male ratios (90). 
 
SLE is associated with the presence of a broad spectrum of autoantibodies, which is a sign 
for the break of immune tolerance. Certain autoantibodies are stable over the disease course 
while others fluctuate and are associated with disease activity (87). Over 95% of SLE patients 
with active disease are positive for anti-nuclear antibodies (ANA) and thus, they are an 
important biomarker for the disease. Indeed, ANA positivity at least at one timepoint is the 
obligatory entry criteria in the new classification criteria of SLE. This is followed by seven 
clinical manifestations and three laboratory factors (89). The first classification criteria for 




Interestingly, autoantibodies can be detected many years before the onset of clinical 
symptoms in the majority of patients (90%). However, the appearance of new types of 
autoantibodies increases up to the disease diagnosis, suggesting that the autoimmune 
processes already start many years before diagnosis (92).  
Thus, SLE pathogenicity can be divided into three main stages, which will be discussed in 
detail in the following sections.  
1. Genetic susceptibility and environmental factors 
2. Break and loss of tolerance to self-antigen 
3. Inflammation, tissue damage, clinical manifestations 
1.2.1 Genetic predispositions in SLE 
Genetic predispositions play an essential role in SLE pathogenesis which is evident from the 
heritability (44%) and relative risk (6%) in first-degree relatives o SLE patients (93). Over 
100 genetic loci have been associated with SLE susceptibility, are often shared across 
ethnicities and with other autoimmune diseases (94).Interestingly, family studies reported an 
increased risk of other autoimmune diseases in the same family with SLE individuals (93). 
Indeed, 44% of the immune-mediated risk single nucleotide polymorphism (SNPs) are 
associated to multiple autoimmune diseases (95). 
In most cases, SLE is influenced by a combination of common polymorphisms. Common 
genetic risk factors affect proteins from following pathways (94): 
 Complement pathway (C1Q,R;S, C2, C3, C4A&B)  
 NF-kappa B signaling (TNFA/P3, PRKCB, TNIPI) 
 TLR and interferon I signaling (IRF5, IRF4, TLR7,8,9) 
 DNA degradation, apoptosis and clearance of cellular debris (RAD51B, 
TREX1,DNASE1, ATG5)  
 Immune complex processing and phagocytosis (FCGR2A,ITGAM) 
  B-cell and T-cell function and signaling (PTPN22, TNFSF4, CD44, LYN, BLK, HLA-
DR2/DR3; DRB1) 
 Cytokines (IL-10, IL21, IL-6) 
One of the most impotent risk factors include the HLA region(HLA-DR2 (DRB1*15:01), 
HLA-DR3 (DRB1*03:01), HLA-DRB1*08:01, and HLA-DQA1*01:02 alleles), STAT4 and 




SNPs in the PD-1 gene, a regulator for B and T cells, exhibited a strong correlation as well 
(94). It is noteworthy, that a single mutation is sometimes enough to develop disease. These 
single mutation are within the genes encoding the complement component 1q (C1q) 
subcomponent A (C1QA), C1QB, C1QC, three-prime repair exonuclease 1 (TREX1), or 
deoxyribonuclease 1-like 3 (DNASE1L3) (97). Moreover, certain SNPs also confers a risk 
for specific clinical manifestations of SLE. The Integrin Subunit Alpha M (ITGAM/CD11b) 
risk allele was associated with an increased risk of renal disorder and discoid rash 
(98).TNFSF4 risk allele was associated with renal involvement in SLE patients. The 
expression of TNFRSF4 on CD4+ T cells is associated with nephritis and disease activity 
(98,99). SLE patients with leukopenia exhibited a higher presence of the IL-21 risk allele 
(98).  
In addition to genetic variants, epigenetic changes trough alteration of DNA methylation may 
exert the influence of genetic risk variance (89). 
1.2.2 Environmental factors in SLE  
 
 
Figure 3: Possible environmental risk factors of SLE include ultraviolet (UV) light exposure, 
Vitamin D deficiency, air pollution, silica dust smoking, medication, hormones and infections 
(101) (created by Biorender). 
 
Exposure to strong silica dust, ultraviolet light, smoking, air pollution, vitamin D deficiency, 
nutrients, solvents and viral and bacterial infections such as EBV have been suggested as 






Hormones might concur to the occurrence of SLE given the fact that SLE is more common 
in young women post-puberty (100). Oral contraceptives. and postmenopausal hormone 
replacement therapies have been linked with an increased risk for SLE incidence (101). 
Bernier et al. reported a  strong-dose relationship between new onset SLE and the oral 
contraceptive ethinyl estradiol (102). Interestingly, low levels of dehydroepiandrosterone 
(DHEA), an endogenous steroid hormone precursor, have been linked with predisposition to 
SLE, and clinical studies suggested that treatment with DHEA in mild to moderate disease 
might be beneficial, however DHEA substitution only showed modest effects in the clinic 
(103,104).  
 
Certain drugs (f.e. Procainamide, Hydralzine) are also able to provoke SLE-like clinical 
features and are associated with anti-histone antibodies. Drug-induced lupus is usually less 
severe and resolves in most cases after discontinuation of the offending agent (105). 
 
The microbiome have gained more and more attention over the last couple of years and 
several research groups investigated the link between SLE and commensal bacteria (106). In 
general, SLE patients exhibit a less diverse gut microbiota compared to the general 
population (106). SLE patients are suggested to have an impaired gut barrier. 
A study by Manfredo et al. demonstrated that the commensal bacterium, Enterococcus 
gallinarum, translocate from the small intestine to the liver in some SLE patients and in 
autoimmune-prone mice (107). In mice, this translocation resulted in a systemic type I 
interferon signature and anti-dsDNA production(106). Furthermore, Greiling et al. 
discovered that the human Ro60 epitopes were highly homologous with commensal bacterial 
Ro60 orthologues (108). Anti-Ro60 antibodies from SLE patients were able to cross-react 
with the bacterial version of Ro60 indicating that pathological autoimmunity could arise from 
a pathobiont (an organism that can cause harm in certain situations but otherwise lives as 
symbiont) in predisposed individuals (108,109). 
1.2.3 Autoantibodies in SLE  
A wide spectrum of autoantibodies can be detected in SLE patients. Certain autoantibodies 
have been associated with specific clinical features and are linked to particular genetic risk 






Table 1: Characteristics of Autoantibodies in SLE (adapted from (87) with additional data 
from (110–112) 
Autoantibody Prevalence Clinical relevance Other diseases 
ANA 95% 
Entry criteria in titer 1/80 for 
SLE, according to the EULAR-
ACR classification criteria 
Mixed connective 
tissue disease, 




anti-dsDNA 40-98% Often linked to disease activity And lupus nephritis Rare in other diseases 
anti-





anti–SSA/Ro  25-40% 
Sicca symptoms, subacute 
cutaneous SLE, pneumonitis, 
shrinking lung syndrome, 
lymphopenia, nephritis, 
vasculitis, thrombocytopenic 
purpura, ocular damage, 
congenital heart block, skin rash 
in newborn 
SS, RA, polymyositis, 
scleroderma, subacute 
cutaneous lupus 
anti–SSB/La  10-22% Congenital heart block SS 
anti-Smith  20-30% 
Mortality, serositis, nephritis, 
neuropsychiatric SLE, 
pulmonary fibrosis, leucopenia, 
arthritis, malar rash, discoid 
rash, vasculitis, pulmonary 
hypertension, peripheral 
neuropathy 






Interstitial lung disease, 
neuropsychiatric lupus, fevers, 
myositis, pleuritis, Raynaud’s 
phenomenon, leukopenia 
SS, RA, polymyositis, 
scleroderma 
anti-ribosomal 
P 10-20% Hepatitis, neuropsychiatric SLE Hepatitis 
anti-
phospholipid  30-40% 
Thrombotic events, pregnancy 





anti- C1q 33% Nephritis SS, RA, vasculitis 






anti-CCP 5.5% Erosive or deforming arthritis RA 
Abbreviations: ANA: anti-nuclear antibodies, SS: Sjogren syndrome RA: rheumatoid arthritis, APS: 
antiphospholipid syndrome, C1q: anti-complement component 1q, RF: rheumatoid factor, CCP: cyclic 
citrullinated peptide; snRNA: small nuclear ribonucleoproteins, anti-SSA/SSB: Anti–Sjogren’s-syndrome-
related antigen A/B autoantibodies 
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1.2.3.1 Anti-nuclear antibodies (ANA) 
ANA comprise a heterogenic group of autoantibodies targeting antigens in the cell nucleus 
and are divided in two main groups(113):  
1. DNA and Histones  
2. Extractable nuclear antigens  
ANA can be present in several autoimmune diseases, cancers, drug-induced or infectious 
diseases as well as in of healthy individuals (113,114). They are detected by 
immunofluorescence antinuclear antibody test or enzyme linked immunosorbent assay 
(ELISA). For the immunofluorescence antinuclear antibody test, human laryngeal carcinoma 
cells (Hep2 cells) are incubated with patient serum. The bound autoantibodies are then 
captured by fluorescent-conjugated detection antibodies and visualized by fluorescence 
microscopy (115,116). The resulting staining patterns identify different ANA subtypes and 
can be used to diagnose different diseases. A homogenous nuclear pattern is associated with 
anti-DNA, anti-histone and nucleosome antibodies and common in SLE (especially drug 
induced SLE), RA and juvenile chronic arthritis (115). Fine, tiny speckles indicate 
autoantibodies binding to nuclear proteins such as RNP, Smith, SSA/Ro, SSB/La, Scl-70, Jo-
1, ribosomal-P and are linked to SLE, myositis, and SS (113,115).  
The detection of different ANA subtypes in this assay, makes it a valuable diagnostic tool.  
A positive ANA test is nowadays an entry requirement in the new classification criteria of 
SLE (3). However, ANA antibodies can also be frequently detected in a healthy individual 
especially after infections and other autoimmune diseases. Thus, a positive ANA test alone, 
without clinical symptoms, has no diagnostic value (117).  
1.2.3.2 Anti-DNA antibodies  
As mentioned above, anti-DNA antibodies are a subtype of ANA antibodies and they can 
either bind single- or double-stranded DNA. Anti-dsDNA antibodies can be detected in 50-
70% of SLE patients, correlate with disease activity in the majority of patients and are rare 
in other autoimmune diseases (87,118). Most, but not all, anti-DNA antibodies have been 
shown to be somatically mutated, suggesting that they originate from germinal center 





1.2.3.3 Anti-SSA/Ro and anti-SSB/La antibodies  
Anti–Sjögren's-syndrome-related antigen B autoantibodies (Anti-SSB/La) are almost always 
found together with anti–Sjögren's-syndrome-related antigen A autoantibodies (anti-
SSA/Ro) while anti-SSA/Ro can also be present independently. Both autoantibodies are able 
to cross the placenta resulting in neonatal lupus and atrioventricular heart block in the child 
(87).  
1.2.3.4 Anti-phospholipid antibodies 
Antiphospholipid antibodies are heterogenous group of autoantibodies composing of 
autoantibodies which bind to: 
1.  anionic phospholipids (i.e. cardiolipin, phosphatidylserine)  
2. phospholipid binding proteins (i.e. β 2 Glycoprotein I (β2GPI), Annexin V, 
prothrombin) 
3.  phospholipid – phospholipid binding protein complexes 
The persistent presence of antiphospholipid antibodies is associated with recurrent venous 
arterial and small vessel thromboses and/or pregnancy complications such as spontaneous 
miscarriages, preeclampsia  and less frequently maternal thrombosis (120). Antiphospholipid 
antibodies are found in around 30-40% of SLE patients from which 20 to 50% develop 
thrombotic complications (121). In SLE patients, antiphospholipid antibodies are associated 
HLA-DRB1*04 and HLA-DRB1*13 alleles (122).  
Three autoantibodies are currently part of the classification criteria of antiphospholipid 
syndrome (APS) and SLE (3): lupus anticoagulant, anti-cardiolipin and anti-β2GPI. LA assay 
measures the clotting time in patients, which is prolonged in APS patients. Since it is a 
functional test, it detects the presence of several different antiphospholipid antibodies 
inducing antibodies against prothrombin, β2GPI but also against protein C/S, Annexin V and 
protein-protein complexes such as β2GPI – cardiolipin or phosphatidylserine – prothrombin. 
The presence of those antibodies is believed to prolong the activation of the coagulation 
cascade by interfering with its phospholipid-dependent steps (120,123–125). 
1.2.3.5 Rheumatoid Factor (RF) in SLE  
RF can be detected in SLE patients with different frequencies depending on the isotype: IgM 
17.9%, IgG 20.5% and IgA 20.5%. Witte et al. found an association between IgA RF and 




1.2.3.6 Anti-citrulline-reactive autoantibodies (ACPA) in SLE  
ACPAs are present in a subgroup of SLE patients and have been associated with erosive 
arthritis and deformations (126–128). However, ACPAs can exists in lupus arthritis patients 
without erosion(129–131). Interestingly, CCP positivity and erosion were associated with 
HLA-DRB1*0401 and HLA-DQB1*0302 shared epitopes alleles in SLE patients(132).  
In addition, high CCP titers have been linked to a small subgroup of patients (Rhupus) 
which features RA and SLE characteristics simultaneously in the same patient (125,128).  
1.2.4 Impaired clearance of apoptotic debris in SLE  
In some SLE patients, an impaired clearance of apoptotic bodies has been described and 
suggested to be responsible for the break of tolerance. Macrophages from SLE patients 
exhibit a reduced phagocytic activity (134,135) and an accumulation of apoptotic debris in 
tissue, such a skin and bone marrow (136,137). Moreover, it has been demonstrated, that 
NET formation, a specific cell death in neutrophils, is increased and insufficiently cleared in 
SLE patients(138). Bauman et al. investigated lymph node biopsies from SLE patients and 
found that a subgroup of patients presented a reduced number of tingible body macrophages, 
a specific type of macrophages which are mainly present in germinal centers (GCs) 
(139,140). This was linked to a reduced clearance of apoptotic cells and an accumulation of 
apoptotic bodies in the GCs (141). The lack of tingible body macrophages in addition to the 
presence of apoptotic bodies could serve as a survival signal for autoreactive B cells binding 
self-antigen and especially nuclear content (142). However, the impaired clearance could 
have also originated from the disease itself, e.g. by autoantibodies inhibiting the clearance of 
apoptotic bodies (141)  
1.2.5 Type I interferon (IFN) signature in SLE  
SLE patients display increased levels of type I Interferon as well as elevated expression of 
interferon related genes in blood and tissue (138,143,144). IFN-α activity is higher in younger 
patients and IFN-α levels correlate in some studies with disease activity, but in general show 
a rather stable pattern over time (81,145,146). Type I IFN are normally involved in the host 
defense mechanism against viral infections. In peripheral tissue of SLE patients, infiltrating 
plasmacytoid dendritic cells (pDCs) represent the main source of type I IFN (147). Other 
cells such as monocytes and neutrophils have also the capacity to produce type I IFN. 
Interestingly, cancer patients treated with IFN-α can develop a lupus-like syndrome with the 
presence of anti-nuclear autoantibodies which suggests that high levels of type I IFN could 
be able to break down tolerance mechanisms and provoke autoimmunity (81,148) Type I IFN 
production can be induced by immune complexes in particular in combination with necrotic 
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or apoptotic cell content (149,150). IFN can then act either directly or indirectly on B cells, 
by inducing the B-cell activation factor (BAFF), reducing the BCR activation threshold and 
warrants naïve B cells to respond against TLR7 ligands(143,151,152). Furthermore, IFN 
production in bone marrow of SLE patients by neutrophils has been linked to a reduction in 
frequency of early B cell subsets (153).  
 
Besides type I IFN, IFN type II and III have also been associated with SLE and correlated 
with disease activity(154,155). Interestingly, IFN-γ levels, a type II IFN, are increased years 
before the diagnosis of SLE while in the more proximate pre-disease phase, elevated levels 
of type I IFN are detected (153). Recently, Oke et al. showed that high levels of different 
IFNs are associated with distinct clinical features (155). On the one hand, high IFN-γ and 
high type I IFN scores, measured by upregulated IFN genes in cell cultures after exposure to 
SLE serum, correlated with nephritis and arthritis. On the other hand, high IFN-α levels were 
linked with active mucocutaneous inflammation and a more benign cardiovascular profile 
and isolated IFN-λ1 levels were associated with less severe disease (155).  
1.2.6 B cell abnormalities, disfunction and hyperreactivity  
B cells are important player in the pathogenicity of SLE and contribute to the disease in 
numerous ways (88). B cells secrete autoantibodies, process and present antigens to T cells 
and produce anti- and proinflammatory cytokines (156). In addition, several genetic risk 
alleles are associated with B cells signaling and can lead to B cell hyperresponsiveness in 
SLE (82).  
 
During B cell development in the bone marrow (BM), early B cells undergo clonal deletion 
and receptor editing (157). This process is regulated by central tolerance checkpoints. In 
healthy individuals, this checkpoint eliminates around 20-50% of autoreactive B cell clones 
(158). A second checkpoint occurs in the periphery during the transition to mature B cells. 
Self-reactive clones are eliminated or silenced by anergy. Break of tolerance has been 
described in SLE (159). SLE patients show defects in several tolerance checkpoints resulting 
in the accumulation of self-reactive and polyclonal B cells in the periphery regardless of the 
disease status (160–162). Overall, SLE patients exhibit a higher number of self-reactive and 
polyreactive naïve B cells suggesting that more autoreactive B cells might enter the germinal 
centers (GC). GCs are the primary site of clonal B cell expansion and affinity maturation. 
Thus, they play also an essential role in autoreactive B cell development and repertoire. B 
cells in the GC circle between dark zone and the light zone. In the dark zone, B cells divide 
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and obtain somatic hypermutation whereas they undergo selection of high affinity antigen 
BCRs in the light zone (157,163). B cell entry into the GC and selection of B cells is highly 
regulated by T cells, dendritic cells, macrophages and stromal cells (157). In SLE, GC 
tolerance mechanisms seem to be subverted. In healthy individuals, naïve- autoreactive 
clones are excluded in early-GC stages while they contribute to GC reactions in SLE patients 
resulting in an expansion of autoreactive post-GC B cell phenotypes (164). 
 
Specific autoantibodies are frequently mutated, and ectopic GC can be found in the kidney 
of nephritis patients (165,166). It is likely that autoantibodies can be generated from non-
autoreactive, polyclonal and autoreactive precursors (166,167). Mietzner et al. analyzed 
autoreactive IgG antibodies and demonstrated that these autoreactive clones arise from non-
autoreactive or polyreactive precursors, which supports the idea that somatic mutations 
contribute to the autoantibody specificity and reactivity (166).  
 
Peripheral tolerance can be challenged by extrinsic and/or intrinsic factors (168):  
Intrinsic Factors Extrinsic Factors 
• BCR signaling  
• TCR responses  
• Incomplete clearance of apoptotic cells  
• Hyperactive T helper cells and dendritic cells  
• Cytokines (BAFF, TLR stimulation)  
 
Recently, Gies et al reported two dysregulated features of B cells in SLE patients: reduced 
expression of the CD19/CD21 complex already in transitional B cells and defective TLR9 
functions in naïve B cells from untreated SLE patients (169). TLR9 is important in governing 
B cell responses to DNA-containing antigens in the periphery by inducing apoptosis 
(169,170). Additionally, TACI, a specific BAFF receptor, plays a crucial role during B cell 
activation and removal of autoreactive B cells (159). TLR7 also has been shown to be 
instrumental in the pathogenic mechanism of SLE. It is essential for the generation of 
spontaneous GC as well as GC and extrafollicular responses (171,172).  
 
Furthermore, aberrations of specific B cell compartments (Figure 4)  have been associated 
with SLE and were found to correlate with clinical features including disease activity and 





Figure 4: B cell fate starting from the development in the bone marrow to long lived plasma 
cells. Arrows indicating an increase or decrease of the subset in SLE. Adapted from: (174) 
1.2.6.1 Pro/pre and Transitional B cells  
In BM of SLE patients, pro/pre B cells are reduced and an expansion in the transitional B cell 
subset has been reported (153). This phenomenon was linked to an increased IFN-signature 
and high BAFF/APRIL levels in BM (153). The frequency of transitional B cells 
(CD19+CD7 CD24hiCD38hi) is increased in SLE patients compared to RA and healthy 
individuals (175,176). Interestingly, transitional B cells are able to produce IL-6. 
Furthermore, IFN-alpha has been shown to enhance the survival of transitional B cells (177).  
1.2.6.2 Unswitched and switched memory B cells  
Memory B cells (IgD-CD27+) are increased in SLE patients and have been shown to be less 
susceptible to immunosuppressive therapy (178). Memory B cells have the ability to quickly 
differentiate into antibody-secreting cells, or alternatively, enter the germinal center upon 
antigen stimulation, which accelerates the secondary immune responds towards previously 
encountered pathogens (179).  
In SLE, switched memory B cells are increased particularly in LN patients in comparison to 
non-LN and healthy individuals (177). The high frequency might result from the persistent 
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antigen stimulation, chronic inflammation and presence of spontaneous germinal centers in 
the kidney. In addition, Zhu et al. demonstrated a decrease of switched memory B cells in 
new onset SLE patients in comparison to healthy controls and chronic SLE patients (177), 
which could have resulted from an activation and differentiation into antibody secreting cells 
and highlights their potential pathogenic role in the diseases.  
 
Interestingly, non-switched memory B cells (IgD+CD27+) are permanently decreased in SLE 
patients (180). Their origin and function remains unclear even though they might correspond 
to circulating splenic marginal zone B cells (180). 
1.2.6.3 Antibody secreting cells/ Plasma cells  
After antigen stimulation, B cells can develop into short- and long-lived plasma cells .While 
short-lived PC primary accumulate in tissue, long-lived PC migrate to the bone marrow into 
specific niches where they can survive for many years and are responsible for persistent 
antigen-specific antibody titers (181). Plasmablasts are precursors of circulating plasma cells 
in the blood which will reach either the bone marrow, spleen or lymphoid tissue and can be 
either long or short lived (156).  
Plasmablasts are elevated in peripheral blood of active SLE patients and are associated with 
increased autoantibody production (173,182,183). A recent study by Tipton et al 
demonstrated that active SLE patients display an increase in newly generated antibody 
secreting cells, with low somatic hypermutations and an expansion of autoreactive VH4-34 
cells. A substantial fraction of these antibody secreting cell was derived from newly activated 
naive B cells, which display a similar phenotype to double negative 2 (DN2) B cells (which 
is explained in the next section) (184,185). 
Interestingly, different autoantibodies show different pattern of expression, some which 
correlate with disease activity and fluctuate (anti-dsDNA) and some which have a stable 
expression over time and are not as affected by immune suppression (anti-RNP, anti-
SSA/SSB). This phenomenon might suggest that more pathogenic autoantibodies are 
produced by short lived plasma cells and plasmablasts which might evolve from a new wave 
of activation of naive or memory autoreactive B cells (118).  
A recent study by Mei et al. discovered that a proportion of plasmablasts in peripheral blood 
of SLE patients which exhibited a mucosal phenotype similar to antigen-specific 
plasmablasts which can be found after oral vaccination (177). This suggests that a proportion 
of plasmablasts in SLE patients might originate from mucosal sides of the body.  
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1.2.6.4 Double Negative (DN) B cells  
Expansion of the IgD-CD27- (DN) B cell population is associated with clinical 
manifestations and severity of SLE (186,187). The DN B cell population consists of a 
heterogenic group of B cells including the so called ‘atypical memory B cells’, DN2 cells or 
age-associated B cells (ABCs). Different research groups have identified similar B cell 
subsets enriched in SLE patients using different surface and intracellular markers: 
Fleischer et al. described an enriched B memory subset in SLE patients, expressing high 
levels of spleen tyrosine kinase (Syk), high levels of CD19 and CD20 but low levels of CD27 
and CD38 and exhibited enhance differentiation into antibody-secreting cells. Jacobi et al. 
discovered ‘activated memory B cells’ in the DN subset using the marker CD95. These B 
cells also expressed low levels of CD21 and CXCR5. Interestingly, DN CD95+ B cells were 
primarily isotype switched and showed similar mutation patterns to typical IgD- CD27+ B 
cells (181). Jenks et al. described an enrichment of DN B cells in SLE patients which is 
primarily caused by the CD11c+CXCR5- (DN2) subset (188).  
Later studies revealed that these B cells represent precursors of antibody forming cells which 
are enriched in the autoreactive BCR repertoire (189–191). This novel B cell population 
correlated with clinical outcomes and disease activity in SLE (192). The exact phenotype and 
the challenges of identifying these cells are discussed in detail in the next section.  
1.2.6.5 Age associated B cells, T-bet expressing B cells, exhausted B cells, DN2, 
“activated memory” - How should we call them?  
A B cell subset expressing T-bet was first described in 2000 and ascribed to IFN-γ production 
(193). The first indication of the pathogenic role of T-bet expressing B cells was reported by 
Peng et al. in 2002. In this report, T-bet-deficient B cells demonstrated an impaired 
production of IgG class switching (IgG2a, IgG2b, and IgG3) and the absence of T-bet in B 
cells in lupus prone mice reduced autoantibody production, and immune-complex driven 
renal disease (194). Next, an enrichment of CD21 negative B cells has been revealed in 
several autoimmune diseases (195,196). Isnardi et al. analyzed CD21 negative B cells in RA 
and common variable immunodeficiencies (CVID) patients and found germline autoreactive 
antibodies, which recognized nuclear and cytoplasmic structures as well as unresponsiveness 
towards BCR or CD40 stimulation(196). In 2008, CD11c+ “plasmablasts” were described in 
the spleen of mice after a bacterial infection with Ehrlichia muris (193) and an expansion of 
“exhausted memory B cells” with the phenotype CD21lowCD27- in HIV patients (193). In 
2011, two independent groups discovered a novel B cell subset, expressing CD11c and 
lacking the expression of CD21 and CD23. The subset was led by the transcription factor T-
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bet and accumulated with age (188,197), and thus were called age-associated B cells (ABCs). 
Besides their correlation with age, an increase in ABCs was soon found in several 
autoimmune diseases (SS, RA, SLE, MS) as well as after various infectious diseases (malaria 
and HIV) (198,199).  
 
This ´atypical B cell subset´ does exist in healthy individuals. CD21 negative B cells exist in 
healthy individuals and account for approximability 5% of human B cells. The CD21- subsets 
were further divided in CD38-CD24+ (mainly CD27+ IgD+ IgM+) and CD38-CD24low 
cells (switched, CD27-). Stimulation of TRL-7/8 and IL-21 induced differentiation into 
antibody-secreting cells (193). CD21 is a BCR co-receptor binding fragments of the 
complement C3 and thereby lowers the threshold for antigen stimulation(193). CD11c+ B 
cells were also investigated in healthy humans and the analysis by Golinski et al. revealed 
that CD11c+ B cells are a heterogenic population which primarily exhibit the phenotype of 
memory B cells and overexpress genes involved in B cell activation, differentiation and 
antigen presentation (194). 
 
In SLE, Wang et al. described an expanded population of CD11chigh T-bet+ cells and 
performed an in-depth analysis of CD11chigh T-bet+ cells (200). This population was enriched 
in autoreactive clones and correlated with clinical features. In response to IL-21, CD11chigh 
T-bet+ cells were demonstrated to differentiate into Ig-secreting autoreactive plasma cells. 
Moreover, CD11chigh T-bet+ cells did not correlate with age (200). 
Jenks et al. explored the expanded double negative (CD27- IgD-) subset in SLE patients using 
the markers CD11c, CXCR5 and divided the DN population into DN1 (CXCR5+CD11c-) 
and DN2 (CXCR5-CD11c+) cell subsets (188). While the DN population in healthy 
individuals primarily accounted for DN1 cells, DN B cells in SLE had an increased 
population of DN2 cells. DN2 cells express low levels of CD21, CD24, CD38, and CD62L 
but have a higher expression in HLA-DR, CD86 and CD69 indicating a resemblance of DN2 
to ABCs (188). Similar to CD11high T-bet+ cells, DN2 cells rapidly differentiated into 
antibody secreting cells following IL-21 and TLR7 stimulation (188). The importance of 
TLR7 signaling for the development of ABCs has previously been described (189). 
Furthermore, DN2 frequency correlated with serum type I interferon activity and higher anti-





Figure 5: Characteristics of double negative 2 (DN2) / age/autoimmune-associated B cells 
(ABCs). The ABC- phenotype can be induced by IL-21, IFN-γ and TLR7 or anti-CD40 and 
anti-IgM. ABCs are described by the up and downregulation of specific expression markers 
as well as the transcription factor T-bet. In response to IL-21, IFN-γ and TLR7 stimulation 
or T cells, ABCs have been shown to quickly differentiate into antibody producing cells.  
 
In conclusion (Figure 5), this ‘atypical` B cell subset has been shown to express CD11c, 
CD20, CD95,FcRL5 and CD86, the transcription factor T-bet and expresses low levels of 
CD21, CD23, CD38, CD40 and CD27 (188,189,197,200). Furthermore, two BAFF receptors 
were found on this B cell subset (200). They are enriched in autoimmunity and after antigenic 
stimulation. They are plasma cell precursors due to their ability to quickly differentiate into 
antibody secreting cells through the stimulation of TLRs and cytokines. Furthermore, ABCs 
have been demonstrated to contain autoreactive B cells and are likely to contribute to the 
pathogenicity of autoimmune diseases (199).  
 
Up to this moment, different research groups use different identification marker and names 
for this unique B cell subset. This provides several draw backs and challenges. Using only 
one single marker, can result in an extremely heterogenic population of B cells. Furthermore, 
it is difficult to compare and find relevant studies if different markers and names are used to 
identify this subset. Thus, I believe it is of great importance to come to a common consensus 
about what markers are best to include in identifying this unique B cell subset by comparing 
RNA seq and flow cytometry data. In this thesis, this unique B cell subset will be referred to 
as ABCs, short for autoimmune-/age-associated B cells, if the markers CD11c, CD21 were 
used and DN2 if the markers CD11c and CXCR5 were used. 
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1.2.7 T cell involvement in SLE  
 
Figure 6: T-helper cell phenotypes. Activated naive CD4+ T cells can differentiate into 
various T-helper cell subsets which fulfil different effector functions.  
T cells and T:B cell interaction are essential players in SLE. Several genetic predispositions 
might lead to abnormal T-cell signaling and/or interactions in SLE patients, such as antigen-
presentation to T cells through the MHC molecules. T cells are key players in regulating 
immune responses by driving inflammatory and regulatory processes as well as antibody 
production. In SLE patients, T cells have been shown to exhibit a number of biochemical and 
functional abnormalities (201). T cell transcriptome analysis by Bradley et al. demonstrated 
that T cells from SLE patients show alterations in several pathways related to mitochondria, 
metabolism, DNA replication and cluster in different patient subgroups (202), which 
highlights the heterogeneity of the disease.  
 
Naïve CD4+ T helper (Th) cells can differentiate into various effector/memory and 
regulatory T-cell subsets which are indicated in Figure 6.  
In SLE patients, Th cells are skewed towards the Th17 phenotype with downregulation of 
Th1 and T regulatory (Tregs) cells (203). Th17 cells are able to produce the cytokines IL-17, 









Th17 and the cytokine IL-17 are enriched in peripheral blood of SLE patients and in kidney 
biopsies and contribute to tissue inflammation and organ damage (80,201).   
 
Tregs, play an important role in suppressing and regulating the immune system and are 
defined by the expression of CD25 and the transcription factor FOXP3 and can either develop 
from the thymus or at the side of inflammation (179). In SLE, Tregs are especially decreased 
in peripheral blood of patients with active disease (204,205). Tregs and Th17 cells are 
interlinked with each other. Th17 cell polarization is induced by STAT3 and the transcription 
factor retinoid acid related-orphan nuclear receptor γt (RORγt). This polarization can be 
shifted towards T regs via STAT6 and the induction of FOXP3, which is a negative regulator 
of RORγt (206) and an important tolerance mechanism. The Th17/Treg balance can be 
altered by proinflammatory cytokines, such as IL-1β, TGF- β and IL-6 which inhibit the 
FOXP3 (80) and favor the differentiation into Th17 cells.  
 
Function of IL-17, IL-21 and IL-23  
 
IL-23 promotes Th17-cell mediated tissue inflammation as well as Tfh and DN T cell 
expansion (376,377).  
 
IL-21 has broad range of function and acts on several different cell types. Its main 
source of production are T follicular helper cells but is also produced by neutral killer T 
cells, CD8 T cells and Th17 cells (179). IL-21 has shown to induce differentiation of 
naïve B cells into ABCs and ABCs into antibody-secreting cells (185,200).  
 
The IL-17 family consist of six members: A, B, C, D and F. IL-17A is the most studied 
cytokine from this family and IL-17F is most commonly produced by IL-17A 
producing cells. IL-17A has been shown to induce production of inflammatory 
cytokines and promotes recruitment of inflammatory cells such as monocytes and 
neutrophils at the site of inflammation (348,378). IL-17A can be produced by various T 
cells including Th17 cells, γδ T cells, double negative (DN) T cells and CD8+ T cells as 
well as by macrophages, mast cells and neutrophils (377). The functions and roles of 




Th17 cells are a plastic and heterogenic T cell subset, and their function depends on the local 
cytokine milieu. Stimulation with IFNα/β results in IL-10 production while IL-23 reduces 
the production of IL-10 and induces IL-17 production (80). Furthermore, Th17 cells are able 
to transdifferentiate and adapt functions from other T cell subsets, such as IFN-γ producing 
Th1 like cells or Tfh-like cells in Peyer's patches to support B cells (205,207).  
Aberrant T cell signaling has been described in SLE and could contribute to the skewing of 
T cells towards IL-17 producing cells (201). Protein phosphatase 2Ac is increased in T cells 
of SLE patients and promotes glomerulonephritis in transgenic mice by increased production 
of IL-17A and IL-17F (208). Dysfunction of Rho-associated protein kinase (ROCK) and its 
pathways has been reported in SLE patients, which leads to increased T cell polarization, 
adhesion and migration (209). In mice, ROCK2 facilitated the activation of IRF4, which is 
obligatory for the production of IL-17 and IL-21 (210). In addition, cAMP response element 
modulator, calcium/calmodulin-dependent protein kinase IV are increased in SLE patients 
and contribute to IL-17 production and differentiation of Th17 and double negative T cells 
(201,211,212). 
 
Double-negative T cells (DN, CD4−CD8-), express the αβ TCR but lack the expression of 
the coreceptors CD4 and CD8. In healthy individuals, DN T cells are suggested to exert 
strong immunosuppressive roles (213). DN T cells are enriched in peripheral blood of SLE 
patients especially in lupus nephritis patients and infiltrate the kidney (214,215). However, 
in contrast to healthy individuals, DN T cells from SLE patients have been identified to 
produce IL-17A and IFNγ and if stimulated in vitro, undergo a vigorous proliferative 
responses suggesting an inflammatory role of DN T cells in lupus nephritis and SLE patients 
(215).  
 
Besides the enrichment of Th17 and DN T cells, an increase of T follicular helper cell 
subpopulation has been associated with SLE. Tfh cells were found in lymphoid aggregates 
and ectopic germinal centers in nephritis lesions as well as in circulation and correlated with 
antibody concentration and frequency of plasmablasts (216,217). Tfh cells are essential for 
B cell maturation, differentiation and antibody production. The interaction of Tfh and B cells 
typically occurs in GC but can also happen at extrafollicular sites. Tfh cells provide survival 
and differentiation signals which is crucial for B cell selection and maturation into memory 
B cells and long-lived plasma cells. In autoimmune diseases, autoantibody production seems 
to originate from GC reactions as well as from extrafollicular pathways (201,218).  
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Additionally to Tfh cells, T follicular helper-like cells, also called T peripheral helper cells 
(TPH) have been identified in blood and tissue of SLE patients and correlate with disease 
activity and B cell differentiation (Figure 7) (219–221). Circulating TPH cells express high 
levels of IL-21, IL-10, succinate and are enriched in IFN-inducible and cytotoxic-related 
genes (219–221). TPH express high levels of PD-1 but are CXCR5 negative. TPH share similar 
functions to Tfh cells by helping B cell differentiation towards antibody producing cells. 
However, TPH help seems to be limited to memory B cells and possible atypical memory B 
cells (222).Tfh and TPH cells co-exist in blood and inflamed tissue. TPH are localized extra-




Figure 7: Differentiation pathways of T follicular (Tfh) and T peripheral (TPH) helper cells 
(adapted from (222)). While Tfh localize intra-follicular and can give help to naïve and 
memory B cells, TPH localize extra follicular in the inflamed tissues and are limited to memory 








1.2.8 Lupus arthritis  
Lupus arthritis is one of the most common and early manifestations of SLE and has a 
significant burden on the patient’s life quality (223). The clinical presentation of joint 
involvement differs and ranges from joint pain without erosions or deformations to an erosive 
joint inflammation leading to severe functional disabilities.  
 
Typically, SLE patients exhibit a transient or persistent often symmetrical joint inflammation 
in the small proximal interphalangeal and metacarpophalangeal joints of the hand and/or 
knees, but can occur in any joint of the body (87). Generally, arthritis in SLE patients is 
transient, migratory and reversible. However, in some cases, it may take a more chronic 
course, which may resemble rheumatoid arthritis (RA).  
 
Classically, two subtypes of deforming joint involvement are described in SLE. A very rare 
form is called Rhupus and leads to a RA-like pattern of erosive arthritis in the presence of 
RF and/or ACPA and anti-RA33 antibodies (see chapter above ACPA in SLE)(129).  The 
other form is called Jaccoud’s arthropathy and leads to hand deformities due to repeated 
tenosynovitis episodes and is associated with longer disease duration and anti-SSA/Ro, RF 
and antiphospholipid antibodies (223–226). However, only a small proportion of lupus 
arthritis accounts for these subtypes (227). 
 
Little attention has been given to the pathogenic mechanisms of lupus arthritis, even though 
90% of SLE subjects encounter joint inflammation, pain and morning stiffness (223). 
Histologic studies investigated the properties of synovial fluid and membrane of SLE 
patients. SF typically includes low white blood cell counts with a predominance of 
lymphocytes and a normal viscosity (228). In synovial membrane, Goldenberg et al. found 
perivascular mononuclear cell infiltrates as well as fibrin deposits on the surface(223). In 
comparison to RA, SLE synovial membrane contains less lining cell hyperplasia and 
mononuclear cell infiltrates (223,229,230).  
 
A recent study examined the global gene expression profiles in the synovial tissue (ST) of a 
small SLE cohort. Upregulated genes in ST of SLE patients included type I IFN genes while 
genes in extracellular matrix homeostasis were downregulated. In comparison to RA, SLE 
ST showed less infiltrating T and B cells (231). Moreover, Eilersten et al. found a correlation 
between ongoing arthritis and elevated levels of IL-6 in serum of SLE patients (232). This 
observation was confirmed by Ball et al. and IL-6 levels correlated with clinal and ultrasound 
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measures for arthritis disease activity (233). They also measured cytokine levels in SF of 3 
SLE patients and found elevated IL-6 levels and lower levels of BAFF and TNF (231). 
However, due to the low sample volume, future studies have to confirm this finding. IL-6 is 
synthesized locally and predominantly by monocytes, fibroblasts and endothelial cells and 
less frequently by lymphocytes. It is a pleiotropic cytokine and is secreted in an acute phase 
response (234).  
 
Indeed, IL-6 inhibition by Tocilizumab was able to improve arthritis in all 7 lupus arthritis 
patients (235). However, the presence of IL-6 in SF has still to be confirmed and the 
underlying pathogenic mechanisms are still poorly understood, even though joint 
involvement represent a common manifestation in SLE. Thus, there is a need to investigate 
















1.3 B CELL TARGETING THERAPY  
 
Figure 8: Expression of CD19, CD20 and the three different B cell activating factor (BAFF) 
receptors on different B cell development stages. The figure was adapted from (236) and 
(237).  
1.3.1 Rituximab 
Rituximab is a chimeric monoclonal antibody specific for the transmembrane protein CD20 
and was first developed and approved in 1997 for the treatment of CD20-positive-B-cell-
non-Hodgkin lymphoma (184). More recently, rituximab found use in potentially B cell-
mediated autoimmune diseases. In 2006, the Food and Drug Administration (FDA) approved 
the drug for RA patients, who failed TNF antagonist therapy (238). Nowadays rituximab is 
used for treating several autoimmune diseases, such as MS and SLE, in patients which failed 
standard therapies (239,240). Besides rituximab, other therapeutic antibodies (biosimilars) 
directed against the CD20 molecule and towards other B cell targets have been developed 
and are currently available on the market (241). 
 
The mechanism of action of rituximab include (238):  
 Induction of apoptosis  
 Complement dependent cytotoxicity  
 Antibody dependent cellular cytotoxicity  
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1.3.1.1 Rituximab treatment in SLE  
The first use of rituximab in SLE was reported in 2002 (242). Since then, several case reports 
described a beneficial effect of rituximab in SLE patients (243–245). Since B cell dysfunction 
is a hallmark of SLE, rituximab seemed to be a promising drug for the disease. Consequently, 
two randomized control trials were performed. The EXPLORER and LUNAR study explored 
the use of rituximab in moderately to severely active extrarenal as well as lupus nephritis 
patients (246,247). Surprisingly, the clinical trials did not meet their primary and secondary 
endpoints and no differences could be detected between rituximab and placebo treated SLE 
patients (246,247). These discouraging results could have originated from the pitfalls of the 
trial design, limitations in assessing the various clinical end points and the heterogeneity in 
manifestation of the disease (248,249). Despite the failure of those clinical studies, rituximab 
is still used by rheumatologists as off-label treatment for patients who are refractory or 
intolerant to conventional therapies (248). 
1.3.1.2 Function and expression of the CD20 molecule 
Rituximab binds to the surface molecule CD20. CD20 is expressed by the majority of B cells 
in different B cell states starting from pro-B cells to memory B cells (Figure 8)(236), but it 
is lacking on pre-B cells, terminally differentiated plasmablasts and plasma cells. CD20 can 
interact with various proteins including MHC molecules, CD40 and BCR (236). The function 
of CD20 still remains unclear. Several mice studies tried to shed light on the function of 
CD20, however, CD20 knock out mice presented a relatively mild phenotype. Despite that, 
the data suggested that CD20 is required for optimal T-independent and T-dependent humoral 
immunity as well as for efficient BCR signaling (238). In humans, Kuijipers et al. described 
a patient lacking the CD20 protein due to a unique mutation. The absence of CD20 resulted 
in a decreased number of memory B cells in peripheral blood, reduced IgG antibody levels 
and isotype switching. Additionally, this patient showed impaired antibody formation after 
vaccination, suggesting that CD20 on B cells is involved in B cell maturation (238). CD20 is 
mainly expressed by B cells, although a subpopulation of T cells expressing CD20 has been 
previously described (250,251). Such CD20+ T cells are enriched in MS patients in 
comparison to healthy donors. They exhibit a greater migration capacity and the amount of 





1.3.1.3 Effect of Rituximab on lymphocytes  
The effect of rituximab on B cells has been studied in the context of various diseases and 
might differ depending on the pathogenic mechanism of the disease. 
In response to rituximab, the number and frequency of CD19+ B cells decrease (254–256). 
B cell repopulation mostly occurs around 6-9 months after treatment and normal B cell counts 
are reached by around 12 months with full mature B cell recovery. Regeneration of memory 
B cells is delayed and does not reach baseline levels after two years (255,257). Naïve, 
memory and immature B cells are rapidly depleted. However, certain memory B cells seem 
to be more resilient to rituximab treatment or tissue-resident memory B cells enter the 
circulation, since more than 80% of residual B cells show a memory or plasma cell precursor 
phenotype (245).  
 
In lymph node biopsies of RA patients, follicular B cells, unswitched memory and naïve cells 
are depleted while CD27+IgD− switched memory B cells persist in lymph node biopsies after 
rituximab treatment (257). Similar results were observed in BM samples after rituximab 
treatment. Short-term changes included depletion of naïve and unswitched memory B cells, 
while the decrease of memory population was long-term. Pre-switched memory B cells were 
not as affected as pre-germinal center B cells by B cell depletion (258). Autoantibody levels 
drop in some patients upon rituximab treatment, in others they are maintained and clinical 
improvement is not necessarily linked to the absence of serum autoantibodies (259). Besides 
B cells, rituximab influences frequencies of T cells, NK, cells and macrophages phenotypes 
(241). 
1.3.1.4 Rituximab treatment and clinical outcomes  
Although some memory B cells, plasma cells and autoantibody levels persist during 
rituximab treatment, abnormalities in B cell homeostasis are improved one year post-
rituximab in SLE patients, with a decreased proportion of autoreactive memory B cells after 
treatment (260). Differences in relapse vs remission were reported by several different 
groups. An earlier and rapid repopulation can be found in patients with early relapse. In 
general, relapsing was associated with high anti-dsDNA antibody levels and increase of 
IgD−CD27hi plasmablasts (261). Insufficient deletion of autoreactive memory B cells might 
result in earlier relapsing. Indeed, a higher portion of memory B cells and lower frequency 
of immature B cells during repopulation correlated with earlier disease relapses in SLE 
patients (241).  
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In RA patients, clinical response to rituximab was related with the depletion of memory B 
cells (CD19+CD27+ ) in PB and BM (262,263). This suggests that the outcome of B cell 
depleting therapy might depend on the balance between protective and pathogenic B cell 
populations (264).  
 
Importantly, the effect of the autoimmune associated B cells subset - ‘atypical’ memory B 
cells/ABCs - upon rituximab therapy has not been studied yet. ABCs express CD20 on their 
surface but could also be more resistant than their relatives – memory B cells. Interestingly, 
after rituximab therapy, BAFF increases in in SLE, RA and primary Sjögren's syndrome 
(265–267). Patients with expanded autoantibody profile and raised BAFF levels at baseline 
had shorter clinical responses and BAFF levels were higher in relapsing SLE  compared to 
patients at disease remission (261). This suggests, that BAFF inhibition together with 
rituximab might result in higher rates of clinical response. 
1.3.2 Belimumab   
Belimumab is a fully human IgG1 lambda monoclonal antibody directed against the B cell 
activating factor (BAFF). It is the first approved and only targeted biological drug currently 
available for SLE (268).  
1.3.2.1 B cell activating factor and its receptors  
BAFF (BLyS, TALL-1,CD257, TNFSF13B) is a key survival, differentiation and activation 
factor for B cells and belongs to the TNF family(237). It is produced by monocytes, 
macrophages, dendritic cells, T cells, osteoclasts and stromal cells (237). It can exist in both 
a soluble and a membrane bound form (269). Three different receptors bind BAFF and are 
present on several immune cell types. In B cells, the three receptors are expressed during 
different stages of B cell development fulfilling a diverse set of functions (Table 2 and 
Figure 8 (237)).  
 
While BAFFR is expressed from transitional B cell stages to mature B cells stages, it is 
downregulated in plasma cells (270). TACI and BCMA additionally bind the protein A 
proliferation-inducing ligand (APRIL). Interestingly, the survival of switched memory B 
cells have been shown to be independent from BAFFR or TACI (Table 2). In contrast, 
follicular, marginal zone and transitional B cells depend on BAFF-induced survival signals 




Table 2: BAFF Receptors expression, function and APRIL and BAFF binding hierarchy  
 
1.3.2.2 Pathogenic role of BAFF in SLE  
SLE patients overexpress BAFF and BAFF levels correlate with disease activity and 
autoantibody levels (269,271).The pathogenic potential of elevated BAFF has been further 
explored in mice. Administration of BAFF resulted in B cell expansion and increased 
antibody levels. Moreover, BAFF-transgenic mice established a severe B cell hyperplasia 
and lupus-like illness which was categorized by the presence of anti-nuclear autoantibodies 
and immune complex deposits in the kidneys (272,273). Dysregulation of BAFF expression 
has been shown to provoke autoimmunity in animal models. Increased BAFF levels can be 
detected in active and relapsing SLE patients after rituximab treatment, suggest a potential 
pathogenic role of BAFF in SLE (261). Overall, BAFF inhibition represented a potentially 
important therapeutic target in SLE. 
1.3.2.3 Belimumab in SLE  
Belimumab neutralizes BAFF by binding soluble BAFF and therefore blocking it from 
binding to its receptors. Two multicenter phase II trials (BLISS-52 and BLISS-76) met their 
primary end points, however, with rather modest success (274,275). Most importantly, 
belimumab treatment achieved long term success with confirmed efficacy and steroid-
sparing effect (276). A recent longitudinal study followed patients on belimumab treatment 
up to 13 years. The patients who initially demonstrated a satisfactory response continued to 
tolerate belimumab and long‐term disease control was provided (276). However, belimumab 









reach a meaningful clinical effect and given the costs of the treatment, belimumab is rarely 
given as first-line treatment(276).   
1.3.2.4 Effect of Belimumab on B and T cells   
The effect of belimumab on B cell subsets has been demonstrated in early longitudinal studies 
(277,278). The total number of B cells decreases after 3-5 months. Interestingly, the effect 
on B cell subsets seems to separate into two groups. While the frequency of transitional and 
naïve B cells reduces early on, the frequency of unswitched-memory and plasmablasts is 
affected later on by the treatment. Memory B cells seem to be more resilient towards BAFF 
inhibition (277,278). A detailed investigation of the changes in B cell phenotypes upon 
belimumab treatment in combination with clinical response is missing in this field.  
The absolute numbers of T cells seems to not be affected by BAFF inhibition, even though 
BAFFR and TACI are expressed on T cells subsets (277,278). However, a detailed analysis 







2 RESEARCH AIMS 
The overall aim of the thesis is to study lymphocytes and autoantibodies involved in the 
pathogenesis of RA and Lupus Arthritis as well as alterations of lymphocyte phenotypes after 
B cell depletion in SLE.  
 
Specific aim of the studies included in the thesis:  
 
In Paper I, we studied alterations of age associated B cell and specific T cell subsets 
longitudinal after rituximab treatment in SLE patients.  
 
In Paper II, we examined changes of B and T cell phenotypes after belimumab treatment 
using mass spectrometry and correlated them with clinical responses.   
 
In Paper III we explored the cytokine profile associated with T cell responses and cellular 
compartments in synovial fluid of lupus arthritis patients.  
 
In Paper IV we investigated the citrulline reactive B cell repertoire in peripheral blood of 
RA patients in order to assess the BCR diversity as well as studying their antigen-recognition 




3 MATERIALS AND METHODS 
This section gives a general overview and highlights the strengths and limitations of the main 
methods in the thesis. A more detailed description of the exact methodology can be found in 
the corresponding papers.  
3.1 ASSESSMENT OF DISEASE ACTIVITY IN SLE PATIENTS  
In order to measure disease activity, responsiveness and quality of life of SLE patients, 
clinical trials and long-term observational studies make use of assessment tools. For this 
purpose, several indices have been established and revised.  
The physician global assessment (PGA) is a visual analog scale that assesses disease activity 
over 2 weeks and is a sensitive measure to score the patient’s overall condition (279).  
SLE Disease Activity Index (SLEDAI) is one of the most common global indices to assess 
disease activity of SLE patients. SLEDAI was first developed in 1986 and described in 1992 
and evaluates 24 items during the past 10 days. Currently, three different revised versions of 
the original SLEDAI are available: SLEDAI-2K, SELENA-SLEDAI, MEX-SLEDAI (90). 
Unfortunately, the index is not graded, you either have or don’t have the assessed 
manifestation, thus it cannot identify small improvements or worsening of the disease.  
The British Iles assessment group (BILAG) is another more elaborate and graded index 
which is commonly used and evaluates organ specific severity over the past one month (90).  
Due to the benefits and disadvantages of each index, recent clinical trials use a combination 
of assessments as primary outcome in order to investigate efficacy of new biological targets. 
The SLE responder index (SRI) combines SLEDAI for global disease activity, BILAG for 
organ specific changes and Physician Global Assessment for validity (279).  
 
Lupus low disease activity score (LLDAS) is a tool that determines the state of low diseases 
activity. LLDAS should be the aimed for as treatment outcome. It is defined by low SLEDAI-
2K, PGA, prednisone dose as well as no activity in major organ systems, no new SLE  activity 
and a well-tolerated dose of immunosuppressive drugs (280).  
 
In Paper II, we used SRI to evaluate the response to therapy and LLDAS to define low 
disease activity.  
Unfortunately, indices are not commonly used in routine care. It is difficult to ascertain 




3.2 SAMPLE PREPERATION  
Freezing, storage conditions and thawing procedures can influence cell viability, sample 
composition and gene expression (281–283). Several studies have optimized these 
procedures and highlighted that several factors are important for good cell viability and 
sample quality (282–287,287–291). These include the right cell density, the right 
cryopreservation medium, and an optimal cooling rate(292). Storage time in the liquid 
nitrogen tank and fluctuation in storage temperature can also influence the sample (289). The 
thawing procedure itself, also has a substantial impact in recovering viable cells from frozen 
samples (283,287,288). Isolation and thawing of peripheral blood mononuclear cells (PBMC) 
from SLE or synovial fluid mononuclear cells (SFMC) is challenging due to the increased 
clumping of cells, which can be improved by the addition of the enzyme benzonase (288). 
Clumping of cells results from an increase of activated or apoptotic cells. Isolation and cell 
recovery from frozen SLE sample are especially tricky, since many of them are lymphopenic 
(293).  
Moreover, thawing and freezing cycles affect the concentration of cytokines and can alter the 
composition in serum and acellular synovial fluid, thus it is of great importance to use 
previously unthawed samples for cytokine analysis and to thaw them slowly on ice (282,284).  
3.3 MULTICOLOR FLOW CYTOMETRY  
Flow cytometry is a frequently used, powerful application which rapidly analyses size, 
complexity and protein expression of millions of single cells or particles in suspension. Single 
cells pass through one or multiple laser beams and emit light to detectors. With the help of 
fluorochrome-conjugated antibodies specific for extra- or intracellular molecules, different 
populations and features can be evaluated. Currently, advanced instruments can measure up 
to 30+ markers (294).  
 
In this thesis, flow cytometry is used to immunophenotype peripheral blood and synovial 
fluid mononuclear cells as well as measuring of cytokines. In Paper IV, we applied a novel 
method to identify antigen-specific B cells in peripheral blood of SLE patients with the help 
of fluorescently labelled tetramers.  Thus, the following parts describe the general principle 
of flow cytometry, different applications and discusses the pros and cons of the application.  
3.3.1 General Principle of Flow Cytometry  
A flow cytometer consists of three different parts: fluidics, optics and electronics. First, the 
sample is injected into a stream of sheath fluid inside the instrument. Due to pressure 
differences, the sample stream is aligned in the core of the flow stream which forces the 
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particles to arrange in a single fashion. This ensures the passing of only one particle at a time 
through the laser beam. The higher the sample flow rate, the wider the sample stream and the 
higher the possibility to have more than one cell passing through the laser beam at the same 
time. Once the cell passes through the laser beam, light is scattered and captured by detectors. 
The forward and side scatter are used to measure size and granuality/complexitiy of a cell. If 
the cell is labelled with antibodies, the fluorochrome of the antibody is excited by a certain 
laser beam and emits photons to a detector. The photons are then converted into electrons 
and send a signal to the computer where the cells are shown as dots on a dot plot or in a 
histogram and can be analyzed (295).  
3.3.2 Advantages of Flow Cytometry  
It is a fast way to analyze different types of cells or particles in a fluid and can even be done 
in high throughput. The applications in which flow cytometry can be used seem endless. 
Microbiologists use it to identify bacteria, hematologists to analyze platelets and 
microparticles, oncologists to look at chromosome abnormalities, and immunologists to deep 
phenotype immune cells. Using cell sorters, specific subpopulation of cells can be isolated 
and further analyzed for functional assays or sequence analysis in bulk or at single cell level.  
3.3.3 Disadvantages of Flow Cytometry  
One of the biggest disadvantages of flow cytometry is spectral overlap of emitted light from 
the fluorochromes. Different fluorophores are excited by different lasers and emit light of 
different wavelengths which travel through selected band pass filters and reach the 
corresponding detector within a flow cytometer. However, emission spectra of different 
fluorochromes can overlap and spill over to other detectors, which can affect the strength of 
the signal and separation of two different markers can be difficult. Thus, single stains, which 
measure the fluorescent signal in all channels are used to calculate spill over value or so-
called compensation. The values are then subtracted from the sample in order to get better 
separation of the populations (296) and consolidated in a matrix which can be manually 
modified. Besides compensation itself, it is important to carefully design the panel used for 
the experiment, to minimize spectral overlap of fluorochromes and to maximize detection 
and separation of populations.  Low or unknown antigens should be stained with bright 
fluorochromes while high antigen expression should use dim markers. It is also important to 
use a live/dead stain since dead cells increase the background and can falsify results. 
Antibody titration reduces non-specific binding and increases sensitivity (294).  
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In general compensation is complex, and incorrect compensation can lead to false 
conclusions and results. It is essential, to carefully design the experiment, prepare the right 
controls and to check the compensation during analysis.  
 
Over the last couple of years, a new technology called spectral flow cytometry was designed 
to measure the full emission spectrum of a fluorochrome and to create so called “spectral 
fingerprints”. During the analysis, the spectra of the sample is unmixed in order to analyze 
single markers. This enables the distinguishing of fluorochromes which are normally very 
close to each other, permitting the use of several spectrally similar markers simultaneously, 
which would have been impossible with traditional flow cytometry (294).  
3.3.4 Cytokine Bead Arrays 
Cytokine Bead Arrays (CBA) are part of the new multiplex technologies, which are able to 
detect several different cytokines or other substances in one sample at the same time. The 
beads contain integrally different dyes and sizes and are covered with antibodies specific for 
its desired cytokine (297). This allows simultaneous detection of up to 30 multiple analytes 
in one single sample. For Paper III, we decided to use the preconfigured BD Th1/Th2/Th17 
CBA Kit, which included the cytokines IFN-γ, TNF, IL-2, IL-4, IL-10, IL-6 and IL-17A 
(298).  
In comparison with ELISA and Western Blots, CBA has a low sample volume requirement 
(25-30ul) and is less time consuming.  CBA can also be analyzed using any kind of flow 
cytometer while other multiplex assays, such as Luminex, require special detection systems 
(299). The protocol is easy to follow and the flow cytometry analysis rather fast. Also, the 
corresponding software for calculating the concentrations is easy to handle. However, CBA 
display a lower sensitivity and a higher level of detection than ELISAs. Moreover, CBA are 
standardized for plasma and cell supernatant, but not for synovial fluid and Cell debris may 
interfere with the results and might have been the reason why we did not detect IL-2, IL-4, 
IFN-γ and TNF in our samples. In a study by Richens et al. Luminex kits were found to be 
more reliable and reproducible as CBA kits (294).  
3.3.5 Mass cytometry   
In Paper II, we used mass cytometry to study longitudinal changes of B and T cell 
phenotypes from peripheral blood of SLE patients after treatment with Belimumab. Mass 
cytometry combines the principles of flow cytometry and time-of-flight mass spectrometry. 
Instead of fluorochromes, antibodies are coupled to metal isotopes and detected using a mass 
spectrometer.  Due to the use of metal isotopes, compensating is redundant since there is no 
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spectral overlap or autofluorescence. Compared to flow cytometry however, mass cytometry 
is expensive, and the acquisition rate is much lower (300,301). Here, they were run at a core 
facility.  
3.3.6 Analysis of Flow Cytometry Data  
Multiple commercially available computer software are available for the analysis of flow 
cytometry data (295). Due to the increase of parameters, the analysis became more complex, 
challenging and time consuming. Usually, flow cytometry data is displayed two-dimensional, 
by plotting two colors against each other. New tools used originally for sequence analysis 
such as t-Distributed Stochastic Neighbour Embedding (tSNE ) and principal component 
analysis (PC) are of great asset nowadays to visualize and evaluate the enormous data sets 
generated by flow and mass cytometry (295,302).  
3.4 CAPTURING ANTIGEN-SPECIFIC B CELLS  
In 1987, Hayakawa et al. were the first group to analyze antigen-specific B cells towards the 
highly fluorescent protein PE using flow cytometry in PE-immunized mice (303). Since then, 
several procedures were developed and various molecules such as recombinant and 
synthesized proteins, lipids, haptens, polysaccharides and virions have been utilized to detect 
antigen-specific B cells by multi-color flow cytometry(304).  
In Paper IV, we constructed citrulline- specific B cell tetramers in order to capture and 
analyze citrulline specific B cells. Newman et al.(305) were the first to use peptide-coupled 
B cell tetramers to identify PE- specific B cell in immunized mice. The idea of using tetramers 
originated from the previously developed methodology of T cell tetramers where HLA 
molecules are coupled to a fluorescently labelled streptavidin (SA) core in order to enable 
direct quantification of antigen-specific T cells. B cell tetramers improve avidity of the BCR, 
brightness of staining and have been found to be more sensitive than monomers (306). In our 
experiments, we separately coupled synthesized, biotinylated, circular citrullinated peptides 
from filaggrin (Cfc1/CCP1) or alpha enolase (CEP-1) to a PE labelled streptavidin (SA) core.  
 
However, in contrast to analyzing antigen-specific T cells, a significant B cell population will 
bind not only to the epitope of interest, but also to epitopes originating from the tetramer 
complex (SA, fluorochrome, biotin) (307). Two different approaches have been established, 
to reduce this problem. Using the same tetramer with two differently labelled fluorochromes 
and selecting for double positively stained cells, fluorochrome-reactive B cells can be 
excluded (304,308). However, the population will still be contaminated by B cells binding 
SA. Thus, the second tactic incorporates a non-specific control tetramer, the so-called decoys, 
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in the procedure. Decoys are labelled with an additional fluorochrome to alter the emission 
spectrum and are excluded during cytometric analysis to distinguish irrelevant B cells from 
the B cells of interest (307). For the decoy tetramers in Paper IV, the arginine version of our 
peptides was coupled to our decoy tetramer and the SA-PE core was conjugated to AF647 
(Figure 9). 
 
Figure 9: Representation of the B cell tetramers constructs used in Paper IV. The B cells 
tetramers core consists of a streptavidin (SA) and coupled fluorochromes; PE for the antigen-
tetramer and PE and AF647 for the control tetramer (decoy). Biotinylated circular 
citrullinated (in green) and circular arginine (in yellow) peptides from either filaggrin or 
alpha enolase.  
 
One of the biggest challenges in detecting antigen specific cells, is their rare frequency in 
circulation. Antigen- specific B cells are typically estimated to occur at a frequency of 0.05 
to 0.005% in the normal repertoire (309). Thus, magnetic enrichment techniques are of great 
importance during the procedure (304). Concentrating the cells can either be done for a 
specific fluorochrome or specific cell subset prior flow cytometry analysis. We enriched our 
cells for the fluorochrome PE using magnetic beads. This enrichment step allows significant 
more cells to be analyzed in a shorter time period. 
 
Other things which have to be considered are bright fluorochromes (PE) used for tetramer 
labelling as well as the markers for phenotyping which should have as little spill over into 







4 RESULTS AND DISCUSSION 
In Paper I and II, we investigated the longitudinal alteration of T and B cell subsets in SLE 
patients undergoing B-cell targeting therapy. This is a useful tool to understand the 
mechanism of the treatment as well as identifying responders vs non-responders.  
4.1 INFLUENCE OF RITUXIMAB ON DOUBLE NEGATIVE (DN) AND 
AGE/AUTOIMMUNE- ASSOCIATED B CELL (ABC) SUBSETS  
In Paper I, we studied primarily the effect of rituximab, and chimeric anti-CD20 antibody, 
on double negative B cell subsets as well as on T follicular/follicular-like T cells subsets in 
10 lupus nephritis and 5 non-lupus nephritis patients using multicolor flow cytometry.  
SLE is characterized by enrichment of certain B cell phenotypes such as double negative B 
cells, plasmablasts and ABCs (CD21-CD11c+) which correlate with disease activity 
(182,185). In our SLE study cohort, DN accounted for 12% of CD19+ B cells at baseline, of 
which 20% expressed CD11c+ without CD21 (ABCs). A small but distinct population of 
plasmablasts (CD27++CD38++) was observed in our patients reaching from 0.14-5% of 
CD19+ cells. 
 
First, we wanted to assess the efficacy of rituximab in depleting B lymphocytes in our patient 
cohort. B cell frequency reduced from a median of 11.3% (IQR: 5.55-21) to 0.74% (IQR: 
0.67-0.94) after 2-4 months. Three patients retained a B cell frequency of 2-5%. Variability 
in B cell depletion has been previously described in SLE patients and might result from 
polymorphism in the Fc gamma IIIa receptor or possible complement defects (260,310,311). 
Similar to previously published results (245,255,312), the frequency of B cells predominantly 
decreased in the naïve (IgD+CD27-) B cell subset while the frequency of the remaining B 
cells increased, i.e. the plasmablasts (CD38++CD27++,9%), memory (IgD-CD27+, 32%) 
and DN (IgD-CD27-, 14%).  
 
Repopulation of B cells has been shown to occur around 6-9 months after rituximab treatment 
(255,313). In our study, an increase of naïve B cells was observed from around 6 months 
onwards. After approximately one year, the naïve B cell population accounted for ~80% of 
CD19+ B cells. At baseline naïve B cells accounted for a median of 70% (IQR: 61-77) of the 
total B cell population. A distinct regeneration pattern of B cell subtypes after rituximab 
treatment has been previously described (255,314). Immature B cells repopulated first, 
followed by naïve B cells. In contrast, memory B cells were delayed in repopulation and were 
reduced even after two years (255,314). In our cohort, memory B cell frequency were reduced 
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after one year, however without significance. Since we only had a small sample size and less 
patients in the later follow up (5 patients in the >longer timepoint), it is difficult to calculate 
statistical power. Upon rituximab treatment, the proportion of DN in CD19+ B cells first 
increased after 2-4 months but then significantly decreased by 6.3% (p=0.01) after 9-10 
months compared to 2-4 months. The effect of rituximab on DN frequencies and numbers 
has been previously reported (312,314). 
 
The DN enrichment in SLE patients originates from the increase of so called DN2 cells, a 
subset which was described by Jenks et al. (185). They distinguished two DN subsets using 
the surface markers CXCR5 and CD11c into: DN1 (CXCR5+CD11c-) and DN2 cells 
(CXCR5-CD11c+) B cells. Besides CD11c, DN2 cells are negative for CD21- and CXCR5- 
and express the transcription factor T-bet. Thus, they are likely to resemble ABCs. We 
decided to include the marker CXCR5 in our panel together with the typical ABC- markers 
CD11c and CD21. Since we included the marker later in the study, CXCR5 was only 
measured in 10 of the 15 patients, which could have influenced the statistical tests (Figure 
10). Baseline DN2 frequencies correlated with ABC frequencies (r=0.8, p=0.001). After 2-4 
months of rituximab treatment, we observed a significant decrease of DN2/ABCs (ABCs: 
13%, p= 0.03; DN2: 14%, p=0.01). ABCs repopulated after approximately 9 months. DN2 
increased in some patients, while in others the frequency stayed low.  Interestingly, the total 
frequency of CD11c+CD21- did not change significantly after treatment indicating the need 
for multiparameter approaches when examining ABCs.  
 
In contrast to DN2 and ABCs, DN3 and DN CD21-CD11c- B cells increased significantly 
(CD21-CD11c-: 24%, p=0.002, DN3: 6.7%, p=0.03) after 2-4 months of rituximab treatment 
(Figure 10). DN3 cells are suggested to resemble early memory precursor and a recent study 
using single-cell transcriptome analyses indicated a relationship between DN3 cell and 
classical memory B cells (315). Thus, DN3 cells might be more resilient towards rituximab 
treatment, similar to classical memory B cells.  
Surprisingly, the frequency DN1 and CD11c-CD21+ B cells did not change significantly. As 
DN3 cells, DN1 cells have been suggested to be early memory precursors (315). 
After approximately one year, we could also observe a significant expansion of DN 
CD11c+CD21+ cells (6%, p=0.007). DN4 B cells (CXCR5+CD11c+) increased non-
significantly after 2-4 months by 11% (p=0.07). Not much is known about DN4 cells. Stewart 
et al. revealed a high frequency of IgE in the DN4 cells (315), however further research is 




Figure 10. Impact of rituximab treatment on the frequency of double negative B cell subsets. 
DN B cells were gated using the markers CD11c and CD21 while in DN1, DN2, DN3 and 
DN4 subsets were divided using CXCR5 and CD11c. Lupus nephritis patients are indicated 























































































































































































































































Of note, the biggest limitation of our study is, that we did not measure the absolute count of 
B cells. Hence, we were only able to analyze frequencies of the remaining B cells and are 
unable to draw firm conclusions of any reduction of B cell subset counts. 
 
To conclude, the frequencies of ABCs and DN2 cells diminished already after 2-4 months 
after rituximab therapy in SLE patients and repopulate in average after 9 months. Depleting 
of ABCs/DN2 might be beneficial for the patients, since DN2/ABCs can quickly differentiate 
into antibody secreting cells and are enriched in autoreactive clones (185,200). DN3 cells, 
which have been describe recently in severe COVID19 patients, seem to be more resilient 
towards rituximab treatment, however their function remains still unclear (316). Further 
analysis of the different DN cell subsets have to be performed in order to understand their 
origins and functions.  
4.2 EFFECTS OF RITUXIMAB ON T CELLS IN SLE  
B cells have the capacity to produce cytokines, present antigen and interact with T cells 
through co-receptors. On that account it is likely, that T cells are directly, by expressing CD20 
and indirectly influenced by B cell depleting therapy. A small subset of CD20-expressing T 
cells might also directly be affected by this therapy. A decrease of T cell activation marker 
such as HLA-DR, CD40L and CD69 as well as an increase in Tregs upon rituximab treatment 
has been reported and validated in several studies (314,317,318).Here, we investigated the 
influence of rituximab on T follicular helper cells, T peripheral helper cells, naïve, effector 
and central memory T cells as well as on TEMRA.  
 
T:B cell interaction is essential for differentiation and survival of Tfh which are enriched in 
affected tissue and in PB of SLE patients (216,319). A few studies have investigated the 
response of Tfh to rituximab, with different outcomes. Wallin et al. reported, that frequencies 
and numbers of Tfh cells and Tfh subsets were not affected in PB nor in lymph nodes on 
transplant patients receiving rituximab treatment(320).  
In contrast, circulating Tfh in neuromelitis optica spectrum disorder were reduced post-
treatment (321). For that reason, we were interested to study if Tfh frequency is influenced 
by rituximab treatment in SLE patients. Surprisingly, the frequency of circulating Tfh cells 
in peripheral blood of SLE patients was not influenced by rituximab. An imbalance of 
circulating Tfh, towards the Tfh2 subpopulation has been described in SLE, and to correlate 
with elevated DN B cells (216). Here, we did not include markers to study subtypes of Tfh 
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and it might still be possible, that Tfh subtypes might be influenced differently by cytokines 
and T:B interactions.  
 
A T-follicular-like cell subset has been recently discovered in SF of RA patients (322). Such 
PD-1high CXCR5- CD4 T cells are enriched also in peripheral blood of active SLE patients 
and have been associated with relapses and disease activity (217,323). In our study, baseline 
PD-1high CD4+ T cells did not correlate with SLEDAI but the frequency of PD-1high CD4+ T 
cells was reduced after treatment. This observation could either result from an indirect effect 
through dampening of the immune response or a direct effect in which B cells would support 
the differentiation of PD-1high CD4+ T cells.  
Interestingly, two patients with high SLEDAI after 6 months follow up had an increase in the 
frequency of CD4+ PD-1high cells. Previous finding reported that  the frequency of TPH cells 
diminished in remission and increased during flare (324), highlighting the pathogenic role of 
PD-1high  CD4+ cells. 
 
When analyzing T cell frequencies, TEMRA (CD45RA+ CCR7-) and effector memory 
(CD45RA- CCR7-) in CD4+ and CD8+ T cells increased slightly after rituximab treatment 
but returned to baseline after approximately one year. A recent study in anti-neutrophil 
cytoplasmic autoantibody (ANCA)–associated vasculitis patients demonstrated a reduction 
of naive (CD45RA+CCR7+) CD4+ T cells and an increase in effector memory (CD45RA–
CCR7–) T cells in patients with disease remission(325). Interestingly, Neel at al. also 
reported a reduction of CD8+ TEMRA after rituximab treatment. We did not observe the same 
phenomena in our cohort of SLE patients.  
 
Around 3-5% of CD3+ T cells express the CD20 molecule, and are effectively depleted by 
rituximab treatment (252,253). Since we did not include CD20 in our panel and we did not 
analyze the absolute number of cells the deletion of these cells might have impacted our 
results. Further limitations of our study are the low sample size and the reduction of patients 
during follow up. Rituximab is often given after and together with other standard of care 
therapies which might have contributed to the patient’s aberrant T and B cell composition.  
 
Overall, we could detect a reduction of PD-1high CD4+ T cells after treatment with rituximab 
while circulating Tfh frequencies were not impacted by rituximab. We still need to perform 




4.3 EARLY AND GRADUAL B CELL ALTERATIONS UPON BELIMUMAB 
TREATMENT  
Belimumab is the first biological agent to be approved by the FDA for SLE patients (268). 
In Paper II, we studied the effect of belimumab on T and B cell phenotypes over time and 
in response to clinical measurements. For this purpose, we obtained blood samples from 23 
SLE patients before and during belimumab treatment (from 3 to 6 occasions) and analyzed 
cell phenotypes using mass cytometry. The clinical response was measured using SRI, 
SLEDAI-2K, BILAG, PGA and low disease activity by LLDAS (which are described in 
detail in the method section).  
 
We evaluted our obtained dataset from two different angles: 
1.  in a biased approach using well-defined cell populations  
2. in an unbiased manner by using specific clustering and dimensionality reduction tools. 
First, we wanted to explore the B cell diversity in our SLE patient cohort before initiating 
belimumab treatment. For this analysis, baseline CD20+ B cells were assembled into clusters 
based on markers and their surface expression levels using tSNE. We could observe a large 
fraction of memory (CD27+) B cells and pronounced cell differentiation. Clusters outside the 
typical memory and naïve repertoire gained our attention. Two clusters displayed expression 
of CD11c+ and low CD21 and CD27, implicating ABCs. In addition, we could also identify 
two small but unique subpopulations expressing CD57 or CD14+CD11c+, which have not 
been previously described. The small CD14+CD11c+ subset also included low levels of 
CD4, consequently this could represent a different cell subset, e.g. monocytes or background 
and we did not explore this subset further.  
 
However, the CD57+ cluster caught our attention. Interestingly, the CD57+ B cell cluster 
lacked differences in other expression markers. On other cells, CD57 is expressed on mature 
cytotoxic NK and on terminally differentiated T cells and theses subpopulations have been 
shown to be expanded in aging and persistent infections (326). So far, expression of CD57 
on B cells has only been reported on specific B cell lymphomas (327,328). In order to confirm 
CD57 expression on B cells in SLE patients, we analyzed baseline sample from five of our 
SLE patient using flow cytometry and could confirm a small but visible expression of CD57 
on CD20+ cells. To further confirm our dataset, we analyzed B cell subsets from multiple 
sclerosis (MS) patients which were run with the same panel and at the same mass cytometry 
facility. We could replicate CD57 expression on B cells in MS at baseline. The CD57+ B 
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cells in MS and SLE patients disappeared upon treatment with dimethyl fumarate therapy or 
belimumab. Given the expression of CD57 on differentiated T cells and NK cells, the 
association with age and persistent infection, as well as expression on lymphomas, one might 
speculate if they are part of the “atypical” B cell repertoire and might share similar features 
to ABCs.  
 
Next, we analyzed well defined B cell phenotypes in response to belimumab treatment. As 
expected, B cell counts gradually decreased during follow-up. Lower B cell counts were 
discovered in patients which reached lupus low disease activity after 24 months of BAFF 
inhibition. Furthermore, we found that patients with higher B cell counts at baseline were 
less likely to respond to belimumab therapy and to reach the lupus low disease activity.  
 
A rapid decline of naïve B cells and ABCs could be observed after 3 months of belimumab 
treatment with a continuous reduction over time. The CD57+ population behaved similarly 
to ABCs in response to BAFF inhibition. BAFF receptors have been reported on ABCs but 
their survival seemed not to be restricted to BAFF in mice (197,329). 
Interestingly, we could observe a rapid and remaining reduction in ABC-numbers in early 
responders while ABCs in late responders decreased more gradually. In non-responder’s 
ABCs seemed to be unaltered highlighting the potential pathogenetic role of ABCs in SLE. 
However, it remains unclear, why ABCs respond differently to BAFF inhibition in patients.  
 
Double negative (DN) B cells decreased more gradually over time and seemed to reach a 
plateau at 12 months which is aligned with previous reports (277). Unfortunately, we did not 
examine the different DN subsets. Given the previous studies about DN2 cells and ABCs 
being part of DN cells it would be of great interest to further dissect this population.  
 
Switched memory B cells seem to be more resistant to BEL treatment. After an initial 
expansion, memory B cells decreased non-significantly after 12 months of BAFF inhibition 
and returned to baseline after 24 months. Similar results have been demonstrated previously 
and memory B cell survival has been shown to be independent from BAFF and APRIL 
(277,330). Noteworthy, when we compared surface expression levels between SLE 
responder index rates vs early responders, IgA+ expression was altered in late responders and 
we found prominent differences in IgA+ CD27+ B cells in early vs late responders. This is 
interesting since humans presenting mutations within the  BAFF-R gene have lower levels of 
IgG and IgM levels but not IgA, suggesting that IgA producing cells might not be dependent 
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on BAFF (331). However, our results might suggest that only certain IgA specific cells are 
independent of BAFF.  
 
Plasmablasts counts were not altered in PB by belimumab therapy even though previous 
studies indicated a decrease of plasmablasts at later timepoints (277,278). Jacobi et al. 
reported a gradual decline in total IgM-producing plasmablasts but not in IgG-producing cells 
(277). The survival of plasmablasts is probably maintained by circulating APRIL, which is 
not inhibited by belimumab (277,330,332). 
 
Subsequently, we were interested in the correlation between the expression levels of 
individual markers and the time of treatment. Thus, we analyzed alterations of cell surface 
antigen expression after 0-3 months (early), 3-6 months (intermediate), and 6-36 months 
(late) of treatment. It is noteworthy, that the expression levels did not necessary represent 
changes in B cell subsets but could indicate a relative increase in expression of these markers. 
The expression levels changed primarily shortly after initializing treatment, while only a few 
markers changed expression during later time points. Interestingly, CD38 initially decreased, 
however, after 6-36 months increased. Performing a paired marker analysis, we explored the 
relationship between markers over early, intermediate and late timepoints. This allowed us 
to link the individual expression of surface markers to B phenotypes. CD38 was co-expressed 
with CD21 and CD22, in early timepoints, but oppositely expressed in later timepoints. This 
observation resulted from the depletion of native B cells while transitional type 1 B cells 
(CD38+IgM+IgD+CD22-CD21-CD27-) were resilient to belimumab treatment. An 
increased ratio of transitional B cells was reported in individuals with a deleted BAFF-R 
gene, suggesting that transitional B cells are BAFF independent (331).  
 
The numbers of monocytes, T helper and cytotoxic T cells were not significantly affected by 
the treatment. Nor could we observe any significant correlation between expression levels of 
markers on T cells and BAFF treatment over time. However, certain BAFF-R have been 
described on T cell subsets. TACI was found on activated T cells (333,334) and elevated BR‐
3 expression was described on TFH cells of SLE patients(335). Hence, a detailed analysis of 
T cell subtypes upon belimumab treatment would be of great interest in the future.  
 
Correlating our immunological findings with low disease activity, we observed that patients 
showing lupus low disease activity at 24 months displayed a lower number of naïve cells and 
switched, memory B cells at baseline in comparison to non-responders while the count of 
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plasmablast and DN cells did not differ. Furthermore, decreased CD11c+ expression 
positively correlated with clinical improvement. Disease activity and anti-dsDNA antibodies 
decreased rapidly following belimumab treatment. While disease activity continued to 
decrease during follow-up, anti-dsDNA did not. Both correlated with early immunological 
alterations but not with later changes. This effect could result from a possible depletion of 
follicular B cells, marginal zone B cells or short-lived plasma cells which have been proven 
to be BAFF dependent (336). However, ABCs could also play an important role. ABCs are 
correlated with anti-dsDNA titers, are able to quickly differentiate into antibody-secreting 
cells and exhibited autoreactivity (185,200,337).  
 
In summary, we observed a rapid decrease of B cell numbers in earlier stages of development 
in response to belimumab treatment while late-stage B-cell subsets are more robust and were 
affected later in a more gradual phase. SLE activity showed a rapid and continues decrease 
after belimumab treatment. ABCs decreased rapidly after treatment in early responders. 
However, in late responders, ABCs seemed more resilient against BAFF inhibition. IgA+ 
memory B cells showed a similar pattern as ABCs. Overall high B cell counts predicted 
unfavorable treatment outcomes, highlighting the importance of testing B-cell counts prior 
to belimumab treatment.  
4.4 SYNOVIAL IL-6 AND IL-17A CYTOKINE SIGNATURE IN LUPUS ARTHRIIS  
Arthritis is a frequent clinical manifestation in SLE patients (227). Yet, little attention has 
been given to investigating the pathogenicity of lupus arthritis. In Paper III, we explored the 
inflammatory environment in the affected joints of SLE patients. Hence, we examined T cell 
associated cytokines in synovial fluid (SF) samples from 17 SLE patients in comparison with 
matched serum samples and RA-SF samples (n=10). Here, we discovered that the two 
cytokines IL-17A and IL-6 were abundant in SF of SLE patients. 
 
Elevated serum IL-6 concentrations have been associated with SLE, correlated with disease 
activity and have been reported in inflamed tissue, such as kidney of lupus nephritis and  in 
cerebrospinal fluid of lupus psychosis patients (203,338,339). Our study has now 
demonstrated increased levels of IL-6 in SF of SLE patients with arthritis.  IL-6 is a cytokine 
which is released in acute response. Moreover, in the context of the synovial joint in SLE, 
IL-6 might have a pathogenic role of in mediating local inflammation and damage in the 
affected tissues (340).  
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A previous study by Eilertsen et al. found an association between serum IL-6 levels, arthritis 
and joint deformation in SLE patients (232). In our dataset, although IL-6 concentrations 
were significantly higher in SF compared to serum, serum IL-6 correlated with IL-6 levels 
from SF (r=0.7, p=0.0001). Additionally, IL-6 was also increased in SF from RA patients, 
which is in line with previous findings linking increased IL-6 to chronic synovitis (341). 
During inflammation, IL-6 fulfils several different functions locally and systemically. It 
affect many different cells such as T cells, B cells, synovial fibroblasts and hepatocytes by 
promoting cell differentiation and inducing synthesis of cytokines and acute phase proteins, 
such as CRP (340,342,343). 
 
Similar to IL-6, IL-17A concentrations in serum of SLE patients have been associated with 
disease activity and IL-17A-producing T cells have been identified in kidney of SLE patients 
(344,345). IL-17A can recruit monocytes and neutrophils at the site of inflammation (346). 
In SF of lupus arthritis patients, IL-17A was abundant and we could observe a weak 
correlation between IL-6 and IL-17A (r=0.39, p=0.03, CI=0.02-0.66) but not in between 
serum IL-17A concentrations. IL-6 and IL-17A are closely interlinked. Recently, it has been 
shown that IL-17A can induce production of IL-6 by monocytes and DC (57,58). 
Furthermore, together with TGF, IL-23 and IL-1 beta, IL-6 is able to induce differentiation 
of naïve T cells into the Th17 phenotype (342,343).  
 
Interestingly, IL-17A concentrations seemed to cluster into two groups: low (<80pg/ml) and 
high concentration (>200pg/ml). However, we did not find any significant differences in age, 
disease duration, clinical symptoms, therapy nor serological features which could have led to 
this division. Our study was conducted retrospectively, on a relatively small heterogenic 
patient cohort. Information of disease activity and systematic assessment of joint at the time 
of sampling were lacking and are a major limitation of our study. Thus, we were limited in 
assessing clinical associations and future studies need to be done in order to address this 
issue.   
Besides IL-17A and IL-6, the cytokine assay comprised the cytokines IFN-𝛾, TNF, IL-2, IL-4 
and IL-10. In 41% of SLE patients, low concentrations of IL-10 were detected in SF and serum 
while low levels of IL-4 and IL-2 could be primarily found in sera. IFN-𝛾 was found in four 
SLE patients in very low concentrations while TNF levels were below the limit of detection in 
all of the samples. Surprisingly, TNF was also not detected in RA-SF patients, which normally 
exhibit high levels of TNF in SF (349). However, many of them were on TNF inhibitors at the 
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time of sampling. Due to the low sample size and the use of only one method, it is difficult to 
conclude if these cytokines are not present in SLE-SF or if the method was not adapted to detect 
them.  
Next, we investigated the source of cytokines and explored the cellular compartments in SF 
of SLE patients. Since mononuclear cells in SF of SLE patients are low, we could only 
retrieve three SFMCs samples from two SLE patient, one with two different timepoints. The 
cells were analyzed for T cell phenotypes and if possible, for B, dendritic cell and monocyte 
subsets using multicolor flow cytometry. Due to the low sample size, we were not able to 
perform any statistical test and our findings are more of exploratory nature. Future studies 
have to be performed in order to confirm our results from these two patients.  
 
Autoantibodies play an essential role in the pathology of SLE patients and phenotypic B cell 
abnormalities are common in SLE patients (349). Interestingly, in SF of SLE patients, CD19+ 
B cells were rare (<1%). The small fraction of B cells in SF exhibited a memory phenotype, 
for one patient containing age/autoimmune associated (ABC) CD11c+ B cells. A lower 
frequency of B cells in SF compared to PB has been reported in RA patients although it was 
higher than our findings in SLE patients (68). In RA, RF and ACPA titers are increased in 
SF and a higher frequency of ACPA-IgG secreting cells has been demonstrated in SF of RA 
patients (68,350). Thus, we investigated the presence of rheumatoid factor (RF) in the cohort 
of SLE patients in SF and serum. Only two patients were positive for RF and exhibited lower 
levels in SF compared to sera. Previous studies reported the presence of ANA antibodies in 
SF, however the exact frequency is unknown (228). These finding suggest that B cells either 
do not to accumulate in SF or stay in the synovial tissue. However, future studies have to 
confirm this theory and it would be of great importance to investigate synovial tissue biopsies 
of SLE patients for ectopic germinal centers.  
 
IL-6 is produced by monocytes, dendritic cells, fibroblasts and epithelial cells and less 
frequently by lymphocytes (340). Consequently, we were interested in monocyte and 
dendritic cell subsets in SF. We found that 64-67% of HLA-DR+ cells in SLE-SF were 
classical monocytes (CD14+ CD16-). A study in ST- segment elevation myocardial 
infarction patient revealed that IL-17A is able to induce the production and secretion of IL-6 
from CD14+CD16- and CD14+CD16+ monocytes (351). Approximately 30% of HLA-DR+ 
cells in SLE-SF were non-monocyte cells and consisted predominantly of classical DC 
(CD11c+, cDC). The frequency of plasmacytoid DC as well as the subtypes of cDCs varied 
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between patients. In patient one, cDC consisted largely of cDC1 while the other displayed 
equal proportions of cDC1 and cDC2. cDC2 have been suggested to play an important role 
in inducing Th17 differentiation in the intestine through IL-6 production (352).   
 
IL-6 is not only able to promote polarization of T cells into Th17 cells but is also involved in 
the differentiation of T follicular helper, as well as cytotoxic CD8+ T cells (340). In our 
study, the frequency of CD8+ cell within the CD3+ compartment was enriched in SF of SLE 
patients compared to PB. EOMES and Granzyme A (GZMA) were expressed by ~70-80% 
of CD8+ T cells. EOMES is an essential transcription factor for CD8+ T cell memory and 
effector differentiation (353)  regulating PRF1 (Perforin-1) transcription (94). An enrichment 
of EOMES+, GZMA+ CD4+ T cells could also be detected in SF of SLE patients. In RA-
SF, a fraction of EOMES+CD4 T cells expressed GZMB and perforin-1, which is a sign for 
a cytotoxic phenotype. GZMA has been shown to stimulate IL-6, IL-8, and TNF- α 
production by human PBMC and monocytes (354). Our group recently identified an 
increased frequency of EOMES+ CD4+ cells in healthy donors homozygous for the PTPN22 
risk allele (1858T) as well as in synovial fluid of RA (355). PTPN22 risk allele (1858T) also 
associates with SLE and might contribute to this phenotype in SLE (356).  
 
We could also identify that a high proportion of CD4 and CD8 T cells were PD-1+ HLA-
DR+/- in all SF samples. PD-1 is upregulated in activated T cells and an increase of PD-1 in 
synovial fluid T cells has been reported in SF in other rheumatic diseases (354,357). 
Interestingly, we could identify a distinct population of PD-1high HLA-DRhigh T cells within 
the CD4+ PD-1+ subset. PD-1high HLA-DRhigh ,so called T peripheral helper cells, have been 
described in SF and synovium of ACPA+ RA patients (322). TPH cells are able to promote B 
cell responses and antibody production. In SLE, TPH cells can be found in the kidneys of LN 
patients and correlated with disease activity (217,323).  
 
The frequency of follicular helper T cells (Tfh, PD1+ CXCR5+) was also increased in SF in 
both SLE patients while Th1 cell frequencies (CXCR3+) were comparable between SF and 
PB. In ACPA+ RA patients majority of T cells express CXCR3+  in SF (358). Regulatory T 
cells (Tregs, CD25+ FoxP3+) are increased in SF and is in line with previous findings from 
other inflammatory arthritis (358).  
A majority (35-55%) of CD4+ T cells expressed the surface molecule CCR6, a marker for 
the Th17 cell subset (359). Th17 cells have been previously linked with SLE, other rheumatic 
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diseases and inflammatory arthritis. An enrichment of CCR6+ CD4+ cells as well as Th17 
cells have been described in the affected joint and peripheral blood of psoriatic arthritis 
patients (360). In SLE, Th17 cells have been shown to be enriched during SLE flare and 
diminish after effective treatment (361,362). Previous studies have shown that IL-17 
producing CD4+ cells are primarily constrained to CCR6 (363). In order to investigate, if SF-
derived T cells are capable of producing IL-17A, we stimulated SFMCs (n=1) in-vitro with 
anti-CD3/CD28 beads. Intracellular IL-17A and IFN-γ production was analyzed using flow 
cytometry. IL-17A was produced by the CCR6+ T helper cell subset but was absent in non-
CD4 expressing T cells. Nevertheless, other cells could still contribute to IL-17A production 
in SF as double negative, gamma delta T cells, innate lymphoid cells, neutrophils and mast 
cells have been recognized to produce IL-17A in psoriatic arthritis patients (292). We only 
investigated the production of T cells and the type of stimulation might have influenced the 
capacity of CD8+ cells to produce IL-17A. A recent study discovered that stimulation with 
CD3/CD28 beads did not stimulate CD8+ cells to produce IL-17A in SFMCs from psoriatic 
arthritis patients (363). 
In addition to IL-17A, we also studied the ability of SF-derived T cells to produce IFN-γ. 
Th17 have been reported to be a plastic population, which can adopt functions from other T 
helper cells (207). Th17 can adept Th1 features and produces IL-17A and IFN-γ 
simultaneously. Th17/Th1 cells express CCR6 and CXCR3 (364,365), in SF of SLE patients, 
CXCR3+ CCR6+ were not enriched and IFN-γ production was only observed in IL-17 
negative CD4+ T cells. However, we did observe an abundant production of IFN-γ in CD4+ 
and CD8+ T cells, suggesting that IFN-γ might play an important role in SF of SLE patients.  
CCR4 which is predominately expressed on Th2 cells, can be found on a proportion of Th17 
cells, however without the production of Th2 associated cytokines and CCR4 might rather 
play a role in trafficking (365–367). Here, we found that CCR4 was increased on CD4+ cells 
in SF of SLE patients and around 40% of the CCR6+ T cells co-expressed CCR4. It is also 
noteworthy that 30% of TPH cells co-expressed CCR6, which highlights the plasticity of these 
cells.  
It is important to mention, that our study is rather exploratory and future research needs to 
replicate our results. The main limitations are the low sample size, especially in the cell 
analysis (n=2) and the lack of clinical data including antibody titers, joint involvements and 
diseases activity. Additionally, the patients in our cohort exhibited a long disease duration 
and history of treatments, which could have influenced our cytokine and cellular data. Hence, 
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further investigations in patients with shorter disease duration, less exposure to treatment 
would be required and it would be of great interest to analyze synovial tissue, to investigate 
the presence of ectopic germinal centers.  
Overall, our study explored the immunology underlaying lupus arthritis and suggests an 
involvement of IL-17 as well as a pathogenic role of IL-6 in the affected joint. The presence 
of CCR6+ CD4+ T cells which are able to produce IL-17A hints towards an involvement of 
Th17 cells in synovial fluid. GZMA+ EOMES+ CD4+ and CD8+ T cells are abundant and 
could contribute to the inflammatory milieu in SF of SLE patients. Yet, future research has 
to determine if those cells are of cytotoxic phenotype or fulfill other functions in synovial 
fluid of SLE patients. Lastly, we could identify TPH cells in SF of SLE patients, which have 
been shown to promote B cell responses in SLE. B cells were rare in SF of SLE patients; 
however, they might be present in synovial tissue of inflamed joints. Altogether, our findings 
indicate a contribution of T cells in pathogenesis of arthritis in SLE patients. This suggests 
that lupus arthritis patients may improve with IL-17A or IL-6 inhibitor 
4.5 CHARACTERISTICS OF CITRULLINE-SPECIFIC B CELLS IN RA 
PATIENTS 
ACPAs are associated with more severe disease activity. Even though extensive research has 
been conducted on ACPAs, the contribution of ACPA to the pathogenesis of arthritis remains 
still unsolved and little is known about the anti-citrulline reactive B cells. To answer some of 
these questions in Paper IV, we made use of a tetramer enrichment strategy and combined 
these tetramers with single-cell cloning technologies in order to identify and study rare 
citrulline-reactive B cell clones in RA patients.   
First, we constructed fluorescently labeled peptide tetramers from two previously described 
antigens: citrullinated human filaggrin (Cfc1/CCP1) and alpha-enolase (CEP-1) (Figure 9). 
Subsequently, the constructs were used to detect citrulline-reactive B cells in peripheral blood 
(PB) of seropositive and seronegative RA patients as well as healthy individuals. 
Interestingly, we could detect a small proportion of citrulline-reactive B cells in PB of healthy 
controls where the majority of citrulline-reactive B cells displayed a naïve phenotype 
(IgD+CD27-). Similar results were observed in seronegative RA patients. In the contrary, in 
PB of seropositive RA patients, citrulline-reactive B cells were enriched in particular in the 
switched memory compartment (IgD- CD27+) and the frequency of switched citrulline 
specific B cells correlated with antibody titers and disease activity score. These findings are 




In order to obtain information about the somatic hypermutation, Ig gene rearrangements, 
origin and binding specificities of citrulline reactive B cells, single cell heavy and light chain 
sequences were obtained from single citrulline specific B cells. Therefore, we used nested 
polymerase chain reaction (PCR) amplifications or high throughput RNA-sequencing. As a 
control, Immunoglobulin heavy (IgH) and immunoglobulin light (IgL) sequences from single 
random blood switched memory B cells were simultaneously amplified and analyzed. 
Furthermore, we cloned and expressed recombinant monoclonal antibodies from paired B 
cell receptor (BCR) sequences and analyzed them for citrulline reactivity using ELISA and 
peptide arrays. 
 
The sequence analysis revealed a biased variable (V) gene usage and complementarity-
determining regions 3 (CDR3) length in heavy and light chain of the captured citrulline 
specific B cell which was primarily absent in the random switched memory compartment. 
Interestingly, the gene rearrangements were more diverse in the CEP-1 specific B cells. 
Additionally, citrulline tetramer binding B cells exhibited extensive somatic hypermutation 
which was concentrated to the CDR regions. The average replacement mutation to silence 
ratio was also increased which is a sign for a positive selection pressure. Our group 
demonstrated comparable results in APCA+ B cells originating from SF of RA patients, with 
a higher mutation frequency and biased V gene usage in ACPA+ B cells compared with 
ACPA- B cells (49). 
Next, we used the generated sequences to assess the phylogenetic relationships of enlarged 
heavy and light chain linages. This revealed that the expanded clades originated from a small 
number of unmutated precursor B cells and the clonal divergency occurred as a result of 
somatic hypermutations. Interestingly, further analysis of the BCRs from tetramer captured 
B cells showed that mAb originating from expanded B cell clades were more likely to bind 
citrulline specific epitopes than non-clade-derived mAb. Additionally, citrulline reactive 
mAb (ACPAs) displayed a citrulline dependent multi-reactivity to several peptide epitopes 
and full-length proteins. Several of the generated ACPAs exhibited a broad reactivity against 
citrullinated nuclear antigens and several were investigated further by our group and 
collaborators. Two of our ACPAs (37CEPT2C04, 37CEPT1G09) were explored in detail due 
to their nuclear binding properties and were observed to bind apoptotic cells from humans 
and mice as well as NETs. Moreover, their reactivity appears to be primarily directed towards 
histones(369). Sahlström et al. have shown that monoclonal ACPAs bind to distinct 
consensus peptide motifs which are present on various proteins which explains the difference 




Lastly, we investigated the pathogenic role of four of our generated mAb in-vitro. Previously 
studies reported that ACPAs alone are not able to induce arthritis but enhance tissue injury 
in murine experimental arthritis models(47,69). Hence, we made use of a transient joint 
inflammation model. For this experiment, mice were injected intravenously with murinized 
mAb and 8 days later with LPS in the ankle joint of the left hindpaw. Sensitivity to 
mechanical stimulation was determined and inflammation was scored visually (0-3 scale). 
Two citrulline polyreactive mAbs were able to induce pain-like behavior and increased 
periarticular immune cell infiltration. In contrast, the control antibodies showed a typical 
course of acute arthritis resolution, highlighting the potential pathogenic effect and the 
functional diversity of ACPAs.  
 
Overall, we utilized the tetramer enrichment technology in order to characterize rare citrulline 
specific B cells in blood of seropositive RA patients. Our data suggests that a few autoreactive 
B cell clones undergo somatic hyper mutation and positive selection with the help of T cells 
and GC reactions which can lead to a diverse autoreactive BCR repertoire. Further studies in 
our group revealed that ACPAs are a functionally diverse subset of autoantibodies which 
recognize distinct consensus peptide motifs present on various proteins which leads to multi-
reactivity (48,370). In addition, the generated mAb were and are currently used to investigate 























































B cell dysfunction and abnormalities are frequent in SLE patients. They display a more 
differentiated B cell repertoire with enrichment of age/autoimmune-associated B cells, 
switched memory B cells and plasmablasts. Defects in peripheral and central tolerance have 
also been described in the disease including GC reactions as well as the accumulation of 
polyreactive and self-reactive immature and naïve B cells. Both mechanisms are likely to 
contribute to the disease pathogenesis (162–164). Thus, B cell depleting therapy seemed to 
be a promising tool for the treatment of SLE and other autoimmune diseases. In order to 
understand the effects and clinical outcomes it is of great importance to study the influence 
of B cell depleting therapy on different cell phenotypes, autoantibody titers and cytokine 
levels.  
Paper I:  
 Frequency of age/autoimmune-associated B cells decreases after ritxuimab 
treatment  
 T follicular helper cell frequencies are unaffected while PD-1high CD4+ T 
cell frequency decreases  
Paper II:  
 SLE patients exhibit a pronounced B cell differentiation.    
 Belimumab rapidly effects early B cell development stages while late 
stage B cell stages gradually alter in later time points or remain uneffected  
 B cell counts, CD11c+ and IgA expression correlate with clinical 
outcomes  
Paper III:  
 Elevated levels of IL-6 and IL-17A are found in SF of SLE patients  
 Enrichment of Th17, T pheripheral helper and EOMES+ T cells is 
observed in SF of SLE patients  
Paper IV 
 Citrulline reactive B cells are mainly of a memory phenotype in 
seropositive RA patients  
 The diverse citrulline reactive B cell repertoire originated from a few 
unmutated B cell clones through several rounds of somatic hypermutation 
and positive selection 
 mAb generated from citrulline reactive B cells are highly multi-reactive, 
display different binding patterns and are able to promote pain and cell 
infiltration in a urine experimetnal arhtitis model.  
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Rituximab and belimumab both rapidly reduce the numbers of B cells in the earlier phases 
of development (transitional, unswitched-memory, naïve B cells). While switched memory 
B cells are more resilient towards belimumab and reduce more gradually, they are depleted 
with rituximab. However, it seems that specific memory B cells are less affected by rituximab 
therapy, since the remaining B cells are of a memory or plasmablast phenotype and a higher 
fraction of memory B cells are related to earlier relapses (241,262,263). It is still surprising 
that B cell depleting therapy did only show modest or even no success in SLE patients in 
clinical trials (246,247,268). This result could be due to the lack or delay for depletion of 
late-stage B cells or that B cells in the tissue are more resilient to the treatment. However, at 
the same time, it also highlights that some patients can improve in the disease even without 
plasma cell depletion nor change in the autoantibody levels, highlighting the heterogenicity 
and complexity of the disease.  
 
In our studies, both B cell depleting therapies were able to reduce age/autoimmune-associated 
B cells (ABCs). So far, we were not able to correlate the clinical outcome with the ABC 
frequency after rituximab treatment. In patients with belimumab therapy, decreased CD11c 
expression correlated with clinical improvement, and non-responder seem to exhibit a more 
resilient population of ABCs compared to responders. It is noteworthy, that the anti-dsDNA 
antibody concentration only changed in the first month, when memory and plasma blast 
levels were still rather stable, suggesting the importance of ABCs. ABCs have been shown 
to be enriched of autoreactive BCRs, e.g. in dsDNA binding BCRs. Still, it remains unclear, 
why the number of ABCs decrease rapidly in responders and why they seem more resilient 
in non-responders. Interestingly, high B cell counts are a predictor for shorter clinical 
response upon belimumab treatment in general. The data suggests that a combination of 
rituximab and belimumab could be beneficial in these patients. Indeed, a successful 
combination of belimumab and rituximab has been reported in small case control studies, and 
clinical trials are on their way (NCT03312907, NCT02260934) (371,372). These clinical 
trials were initiated due to the fact that, after treatment with rituximab, patients exhibit higher 
levels of BAFF. High BAFF levels are associated with shorter clinical response and earlier 
relapses in patients treated with rituximab (265–267). A combination of these two treatments 
might also be valuable for patients with high B cell counts.  
 
The question arises: “Are we targeting the right cells and subsets in SLE?” More effective 
targeting of ABCs and plasma cells may be an effective therapeutic strategy for SLE. 
However, autoimmune diseases result from a complex interplay between the innate and the 
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adaptive immune system. Moreover, SLE is highly heterogenous disease with different 
clinical manifestations and immune pathways involved. A personalized approach based on 
the study of clinical manifestations in combination with specific laboratory measurements, 
such as cytokines and cell subsets, could be a useful tool for the clinicians to decide the best 
treatment strategies for each patient. Therefore, it is crucial to understand the pathogenic 
mechanisms and compounds involved in the different manifestations, disease mechanisms 
and patient subgroups.   
 
Lupus arthritis is a common clinical manifestation in SLE and influence the life quality of 
the patients (227,373). Little is known about the pathogenic mechanisms of the disease. For 
that reason, we analyzed SF samples from SLE patients and found elevated levels of IL-6 
and IL-17A as well as an enrichment of Th17, T peripheral helper cells and cytotoxic T cells 
in SF of SLE patients. Although further studies, with a higher sample size and more in-depth 
analysis of the cytokine profile and cells involved are needed in order to confirm our findings, 
they still suggest a potential therapeutic role of IL-6 and IL-17A in lupus arthritis patients. 
Indeed, IL-6 inhibition has been demonstrated to improve arthritis in lupus arthritis 
patients(374). Additionally, IL-17 inhibition seems a promising target for some SLE patients, 
including the potential of IL-17 to promote the survival of long lived plasma cells and a 
clinical trial is currently performed in SLE patients (NCT03866317,(375). 
 
In the future, could we detect and deplete only autoreactive B cells in the patient? Nowadays, 
B cell tetramers are frequently used to analyze antigen specific B cells and are a useful tool 
to study the B cell repertoires, the origin and characteristics of autoreactive B cells in 
autoimmune patients. Using citrulline specific tetramers, we were able to detect and analyze 
citrulline reactive B cells in blood of RA patients. Our study revealed that citrulline reactive 
B cells develop from a restricted number of B cells which underwent several rounds of 
somatic hypermutations. This expansion might be driven by citrulline reactive T cells and 
starts before the development of clinical symptoms. The extensive somatic hypermutation 
and presence of ACPA+ B cells hints towards a continuously active B cell response. How 
exactly joint inflammation and RA is triggered is still unknown. ACPAs alone cannot induce 
arthritis in mice but mAbs originating from tetramer captured B cells were able to promote 
joint inflammation and pain of mice, implicating that they are indeed important in the 
pathogenicity of RA. Further studies with these antibodies demonstrated that ACPAs have 
different binding patterns, functions and might originate from different immune responses. 
Recently, our unit demonstrated, that ACPAs, which bind nuclear antigens, might develop 
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independently from the citrullinating enzyme PAD through neutrophil activation and NET 
formation (369), suggesting that several mechanism can result in a diverse set of ACPAs. 
However, it is still not exactly known how citrulline reactive B cells are able to escape the 
tolerance checkpoints.  
 
To conclude, rheumatic diseases are highly heterogenous with different pathogenic 
mechanisms. Autoantibody production starts before the onset of clinical symptoms and can 
be found in some healthy individuals. Genetic and environmental factors probably contribute 
to the development of autoreactive antibody as well as to the break of tolerance.  
Questions are still remaining:” How tolerance is broken in different individuals? Would it be 
possible to restore tolerance mechanisms in these patients?” These are questions which 
hopefully future research will answer. For now, I think we would already improve clinical 
diagnostic and treatment if we chose therapeutic agents on individual bases. This strategy 
would be based on an in-depth integration of cellular markers, cytokines, complement and 
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